

# Sepsis associated acute kidney injury

Jason T Poston,<sup>1</sup> Jay L Koyner<sup>2</sup>

<sup>1</sup>Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL 60637, USA

<sup>2</sup>Section of Nephrology, Department of Medicine, University of Chicago

Correspondence to: J L Koyner  
jkoyner@uchicago.edu

Cite this as: *BMJ* 2019;364:k4891  
doi: 10.1136/bmj.k4891

Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors

## ABSTRACT

Sepsis is defined as organ dysfunction resulting from the host's deleterious response to infection. One of the most common organs affected is the kidneys, resulting in sepsis associated acute kidney injury (SA-AKI) that contributes to the morbidity and mortality of sepsis. A growing body of knowledge has illuminated the clinical risk factors, pathobiology, response to treatment, and elements of renal recovery that have advanced our ability to prevent, detect, and treat SA-AKI. Despite these advances, SA-AKI remains an important concern and clinical burden, and further study is needed to reduce the acute and chronic consequences. This review summarizes the relevant evidence, with a focus on the risk factors, early recognition and diagnosis, treatment, and long term consequences of SA-AKI. In addition to literature pertaining to SA-AKI specifically, pertinent sepsis and acute kidney injury literature relevant to SA-AKI was included.

## Introduction

Sepsis is a life threatening clinical syndrome characterized by organ dysfunction caused by a patient's dysregulated response to infection. Septic shock is a subset of sepsis with increased mortality characterized by hypotension, in which vasoactive drugs are needed to maintain a mean arterial pressure of at least 65 mm Hg and a serum lactate concentration above 2 mmol/L despite resuscitation.<sup>1,2</sup> These Third International Consensus (Sepsis-3) Definitions published in 2016 mark a refinement of the definition of sepsis from the continuum of systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock that had guided clinical management and research for more than two decades.<sup>3,4</sup> The Sepsis-3 definitions identify the deleterious response to infection more specifically, as they were developed in the context of an enhanced understanding of both the biologic mechanisms of sepsis and the clinical outcomes made evident with the advent of large patient datasets.

Concurrently, the past 15 years have been a period of important progress in the understanding of the incidence, detection, pathobiology, and treatment of kidney dysfunction in the setting of critical illness and in sepsis specifically. From the initial RIFLE definition of acute renal failure in 2004 through the refined KDIGO definition of acute kidney injury (AKI), our ability to recognize and characterize changes in kidney function with traditionally available assessment methods (serum creatinine, urine output) has grown.<sup>5-7</sup> Many serum and urinary biomarkers allow earlier detection of AKI and have the potential to improve supportive care and clinical outcomes.

In this review, written for specialists in critical care medicine and nephrology, we critically review the published literature for sepsis associated acute kidney injury (SA-AKI), with a focus on epidemiology, non-modifiable

risk factors, early detection, pathophysiology, modifiable risk factors, treatment, and prognosis.

## Sources and selection criteria

We searched several online databases from 2000 to April 2018, including PubMed, the Cochrane database of systematic reviews, and the central register of controlled trials. We used keywords and combinations of keywords such as sepsis, severe sepsis, septic shock, acute kidney injury, acute renal failure, kidney failure, dialysis, and renal replacement therapy. We prioritized large scale, multicenter, randomized trials and large high quality epidemiologic studies when available. However, given the breadth of this review and the dearth of large studies in some aspects of SA-AKI, we thought that it was important to include observational and pre-clinical studies that are driving future investigation in this area. We highlighted the limitations of these studies where relevant.

## Definitions

### Sepsis

Although sepsis been appreciated as a cause of morbidity and mortality for centuries, consensus definitions have been available only for several decades.<sup>8</sup> The first consensus definitions defined sepsis on a continuum of physiologic and serologic abnormalities that indicated progressive organ failure. The systemic inflammatory response syndrome (SIRS) indicated the potentially injurious inflammatory response, sepsis was defined as SIRS with infection, severe sepsis was sepsis with organ dysfunction, and septic shock was sepsis with persistent hypotension.<sup>3,4</sup> These definitions, with only minor revision, guided bedside clinical practice as well as clinical, translational, and basic research of sepsis for 25 years.

These definitions were critical in advancing our understanding of sepsis, but experience revealed their

**Box 1 | Sepsis-3 definitions and quick SOFA (qSOFA) criteria<sup>1</sup>****Sepsis-3 definitions**

*Sepsis*—Life threatening organ dysfunction caused by a dysregulated host response to infection

*Septic shock*—Sepsis with a requirement for vasoactive therapy to maintain mean arterial pressure  $\geq 65$  mm Hg and lactate elevation to  $>2$  mmol/L despite adequate volume resuscitation

**qSOFA criteria**

- Respiratory rate  $\geq 22$  breaths per minute
- Altered mentation
- Systolic blood pressure  $\leq 100$  mm Hg

limitations as well. One multicenter observational cohort study found that two criteria for SIRS were met in 87% of patients at admission to the intensive care unit (ICU), in 93% during their stay in ICU, and in 100% of patients with infection.<sup>9</sup> Another multicenter cohort study identified infected patients without SIRS, but mortality was the same in this group and in infected patients with SIRS (hazard ratio 0.94, 95% confidence interval 0.77 to 1.15), suggesting that meeting two criteria for SIRS was not predictive of outcomes.<sup>10</sup> SIRS was recognized as a non-specific marker of both infectious and non-infectious inflammation that did not meaningfully predict clinical outcomes. These observations resonated with an increased understanding of the response to injury, whether infectious or sterile. The critical feature that differentiates infection from sepsis is organ dysfunction that results from the inflammatory response.<sup>11</sup>

The Sepsis-3 definitions were an empirically based response to these limitations. SIRS and severe sepsis were eliminated. Sepsis is defined as “life threatening organ dysfunction caused by the dysregulated host response to infection.” Identification of organ dysfunction may be identified as an acute and infection related change of at least 2 points on the sequential organ failure assessment (SOFA) score, which is associated with mortality of approximately 10%.<sup>11 12 13</sup> Screening for sepsis in infected patients may be aided by use of the quick SOFA score, in which the presence of two out of three criteria suggests sepsis. Septic shock is defined as sepsis with hypotension requiring vasopressors to maintain a mean arterial pressure at least 65 mm Hg

and a serum lactate concentration above 2 mmol/L despite adequate volume resuscitation, which was associated with mortality of greater than 40% (box 1).<sup>2</sup> The performance of the Sepsis-3 definition in clinical practice remains a point of discussion and contention, however, as there seems to be a loss of sensitivity relative to SIRS and variable performance based on practice setting (emergency department, inpatient ward, ICU). Furthermore, other novel models may provide even more accurate diagnosis and prediction.<sup>14 15</sup>

**Acute kidney injury**

AKI and acute renal failure have long been recognized as a complication of critical illness independently associated with mortality.<sup>16-18</sup> Similar to sepsis, understanding the epidemiology, pathobiology, and treatment of renal dysfunction in the ICU was predicated on establishing a consensus definition.

The first widely adopted definition emerged from the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group in 2004.<sup>6</sup> Similar to SIRS based sepsis criteria, the RIFLE classification (risk, injury, failure, loss, end stage kidney disease) used readily available clinical (decreased urine output) and serologic (rise in serum creatinine) markers to better characterize what was termed acute renal failure.<sup>6</sup> Subsequent consensus definitions would use the term acute kidney injury, a more inclusive term that underscores the importance of the injury and consequent change in the renal function. Through this lens, the 2007 definitions of the Acute Kidney Injury Network (AKIN) focused on the initial injury previously deemed risk, injury, and failure of the RIFLE classification, terming them stage 1, 2, and 3 AKI.<sup>5</sup> Loss and end stage kidney disease in the RIFLE system were removed along with the partial reliance on glomerular filtration rate (GFR). Additionally, the AKIN criteria included small changes in serum creatinine ( $>0.3$  mg/dL increase in 48 hours) in the definition of stage 1 AKI.<sup>5</sup> Several large observational trials confirmed the validity of the RIFLE and AKIN revised criteria, as increasing severity of AKI was associated with increasing risk of death.<sup>19 20</sup>


Despite high incidence (22%) and significant effect on outcomes, a concern remained that AKI was underdiagnosed owing to inconsistent screening practices and the tendency for these criteria to miss AKI that occurs before arrival at an acute care setting. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for AKI present the most recent consensus definitions, which again attempt to refine the sensitivity and specificity of the AKI definitions. Table 1 summarizes the RIFLE, AKIN, and KDIGO criteria for AKI. The KDIGO definition emphasizes AKI risk assessment and evaluation while extending criteria to include a rise in serum creatinine of 50% or greater over the presumed baseline within seven days of assessment.<sup>7 21</sup> In an international cross sectional study using these criteria, 57.3% of ICU patients met KDIGO criteria for AKI. The adjusted odds ratio for in-hospital mortality was 1.68 (0.89 to 3.17) for stage 1, 2.95 (1.38 to 6.28) for stage 2, and 6.88 (3.88 to 12.23) for stage 3.<sup>22</sup>

Despite this progress, the sensitivity and accuracy of AKI criteria have been generally acknowledged to remain limited by a reliance on the imperfect assessment methods

**Table 1 | Acute kidney injury (AKI) diagnostic criteria: RIFLE, AKIN, and KDIGO**

Staging	Serum creatinine			Urine output (all)
	RIFLE	AKIN	KDIGO	
Definition of AKI	SCr increase $\geq 50\%$ within 7 days	SCr increase $\geq 50\%$ or $\geq 0.3$ mg/dL within 48 h	SCr increase $\geq 50\%$ in 7 days or $\geq 0.3$ mg/dL within 48 h	-
RIFLE-risk; AKIN stage 1; KDIGO stage 1	SCr increase $\geq 50\%$ or GFR decrease $>25\%$ within 7 days	SCr increase $\geq 50\%$ or $\geq 0.3$ mg/dL within 48 h	SCr increase $\geq 50\%$ in 7 days or $\geq 0.3$ mg/dL within 48 h	$<0.5$ mL/kg/h for 6-12 h
RIFLE-injury; AKIN stage 2; KDIGO stage 2	SCr increase $\geq 100\%$ or GFR decrease $>50\%$ within 7 days	SCr increase $\geq 100\%$	SCr increase $\geq 100\%$	$<0.5$ mL/kg/h for $\geq 12$ h
RIFLE-failure; AKIN stage 3; KDIGO stage 3	SCr increase $\geq 200\%$ or GFR decrease $>75\%$ or SCr increase $\geq 4$ mg/dL (with acute rise $\geq 0.5$ mg/dL)	SCr increase $\geq 200\%$ or $\geq 4$ mg/dL (with acute rise $\geq 0.5$ mg/dL) or need for RRT	SCr increase $\geq 200\%$ or $\geq 4$ mg/dL or need for RRT	$<0.3$ mL/kg/h for $\geq 24$ h or anuria for 12 h
RIFLE-loss	Need for RRT $>4$ weeks	-	-	-
RIFLE-end stage	Need for RRT $>3$ months	-	-	-

GFR=glomerular filtration rate; RRT=renal replacement therapy; SCr=serum creatinine.



**Fig 1 | Acute disease quality initiative criteria: incorporating biomarkers into the definition of acute kidney injury (AKI).** Emerging data outside of sepsis associated AKI (SA-AKI) point to the increased risk for adverse outcomes in patients who do not have a change in functional markers of the kidney (eg, serum creatinine or urine output (UOP)). This has led to calls for classification of AKI in terms of changes in function and damage and the resultant 2x2 grid shown. This work has created a new category of patient with “subclinical AKI,” those with elevated damage biomarkers in the absence of a change in renal function (UOP or serum creatinine). This group can be thought of as akin to those with a change in function without the presence of damage (traditionally thought of as “pre-renal azotemia”) and separate from those with intrinsic AKI (a change in both function and damage). Adapted from Endre et al<sup>23</sup>

on which they are built: urine output and serum creatinine. Some people have called for further refinement of AKI in terms of these traditional functional markers, as well as changes in kidney damage biomarkers (fig 1).<sup>23</sup> Although the emergence of data derived clinical risk scores, renal imaging, functional assays, and biomarkers have shown promise, they have yet to become a part of consensus definitions or guidelines. However, they represent opportunities to refine our diagnosis, evaluation, treatment, and prognosis of AKI.<sup>24</sup>

**Sepsis associated acute kidney injury**

Many patients meet consensus criteria for both sepsis and AKI and are deemed to have SA-AKI or septic AKI.<sup>25,26</sup>

Sepsis is associated with up to 50% of AKI, and up to 60% of patients with sepsis have AKI.<sup>25,27</sup> Independent risk factors or clinical consequences of sepsis and AKI, such as hypovolemia or exposure to nephrotoxic therapies, have confounded the relation between these entities.<sup>28,29</sup> Although the pathophysiologic mechanism remains incompletely understood, it seems evident that the deleterious inflammatory cascade characteristic of sepsis contributes to the AKI as well.<sup>30</sup> Patients with sepsis complicated by AKI have a significantly increased mortality relative to patients without AKI.<sup>26,31,32</sup> Furthermore, patients with AKI associated with sepsis have a significantly increased mortality relative to those with AKI of another etiology.<sup>31</sup>

**Epidemiology**

Accurate estimation of the incidence and trend of AKI secondary to sepsis has proved challenging. Even as screening programs and data science help to refine our ability to define AKI associated with sepsis, strictly characterizing AKI as being attributable to sepsis remains difficult given the many confounders common in critically ill patients.

The incidence of sepsis and related morbidity seems to be rising, whereas the mortality rate of patients with sepsis seems to be falling. A comprehensive review of 750 million hospital admissions in the US from 1979 through 2000 found that sepsis increased from 82.7 to 240.4 per 100 000 population, an annualized increase of 8.7%.<sup>33</sup> In-hospital mortality fell from 27.8% to 17.9%. Analyses of data from the subsequent 10-15 years using more robust patient level data from England, New Zealand, Australia, and the US have all shown similar trends, with increasing overall burden of sepsis and decreasing mortality rates.<sup>8,34-36</sup> Rates of AKI and sepsis associated AKI are discussed below.

**Risk factors for development of sepsis associated AKI**

Much of our understanding of the risk and prognostic factors in AKI comes from studies of patients in general wards, mixed ICU populations, or patients undergoing cardiovascular procedures, in whom the baseline kidney function and the nature and timing of injury can be well defined. Patients with SA-AKI are often included but are not the dedicated or exclusive focus of these studies. However, we believe that identified risk and prognostic factors for AKI in a general population likely confer an equal or even greater risk in patients with sepsis.

Furthermore, the heterogeneity of both the patient population and the focus of any given study can lead to inconclusive and occasionally conflicting data about the risk factors for AKI. The pre-morbid risk factors for AKI most consistently identified include advanced age, chronic kidney disease, and cardiovascular disease. Characteristics associated with the acute illness most commonly linked to AKI included cardiovascular failure, liver failure, and sepsis. Table 2 summarizes these and other risk factors. Potentially modifiable risk factors related to the treatment of patients with sepsis are discussed in the treatment section.

Finally, observational data suggest that AKI may predispose patients to an increased risk of sepsis. In the Program to Improve Care in Acute Renal Disease (PICARD)

**Table 2 | Risk and prognostic factors for acute kidney injury**

Factor	Effect on risk or prognosis
<b>Present before acute illness</b>	
Age <sup>18-38</sup>	Developing AKI OR 1.5 (95% CI 1.16 to 1.92) for age ≥65; 1.01 (1.00 to 1.02) for each year Death with AKI OR 1.19 (1.05 to 1.33) for age ≥65; 1.13 (1.01 to 1.26) for each decade
Sex	Developing AKI Data inconsistent
Race	Developing AKI Data inconsistent
Chronic kidney disease <sup>39</sup>	Developing AKI OR 2.9 (2.7 to 3.1) for eGFR 45-59; 6.2 (5.7 to 6.8) for eGFR 30-44; 18.3 (16.5 to 20.3) for eGFR <30 mL/min/1.73 m <sup>2</sup> Death with AKI AKI predictive of mortality, but less predictive for patients with more severe CKD
Diabetes mellitus <sup>40</sup>	Developing AKI OR 10.3 (7.7 to 13.6) for developing stage III AKI Death with AKI OR 1.2 (1.2 to 1.7)
Hypoalbuminemia <sup>24,41</sup>	Developing AKI OR 2.34 (1.74 to 3.14) with drop 1 g/dL Death with AKI OR 2.47 (1.51 to 4.05) with drop 1 g/dL
Chronic liver disease <sup>18</sup>	Developing AKI OR 2.18 (1.16 to 4.10)
Heart failure <sup>18-40</sup>	Developing AKI OR 2.18 (1.12 to 4.44) to 24.0 (18.5 to 31.2)
<b>Caused by acute illness</b>	
Cardiovascular failure <sup>18,40</sup>	Developing AKI OR 1.84 (1.32 to 2.56) Death with AKI OR 1.8 (1.2 to 2.9)
Mechanical ventilation <sup>42</sup>	Death with AKI OR 5.1 (2.0 to 12.8)
Liver failure <sup>37</sup>	Death with AKI OR 1.90 (1.34 to 2.71)
Sepsis <sup>37</sup>	Death with AKI OR 1.87 (1.33 to 2.62) to 2.1 (1.1 to 1.4)

AKI=acute kidney injury; CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; OR=odds ratio.

**Box 2 | Urinalysis scoring systems****Prospective observational cohort studies with discovery and validation cohorts for AKI cast scoring index<sup>51</sup>**

Grade 1—no casts or RTE

Grade 2— $\geq 1$  cast or RTE but  $< 10\%$  of LPF

Grade 3—many casts or RTEs (10-90% of LPF)

Grade 4—sheet of muddy brown casts and RTEs in  $> 90\%$  of LPF**Prospective observational cohort for development of urinary sediment scoring system<sup>52</sup>**

0 points—no casts or RTE seen

1 point each—1-5 casts per LPF or 1-5 RTEs per HPF

2 points each— $\geq 6$  casts per LPF or  $\geq 6$  RTEs per HPF**Prospective multicenter observational cohort for derivation of urine microscopy score<sup>53</sup>**

0 points—no casts or RTE seen

1 point each—1 cast or 1 RTE per HPF

2 points each—2-4 casts or RTEs per HPF

3 points each— $\geq 5$  casts or  $\geq 5$  RTEs per HPF

HPF=high power field; LPF=low power field; RTE=renal tubule epithelial cells

study, 243 (40%) patients developed sepsis a median of five days after the development of AKI. Although the pathophysiology and correlation between these two events remain unclear, mounting evidence suggests that AKI increases the risk of sepsis and its associated adverse outcomes.<sup>29</sup>

**Early detection of SA-AKI**

As both sepsis and AKI are independently associated with increased morbidity and mortality, length of stay, and cost of care, early detection is critical to providing opportunities for successful intervention.<sup>43-45</sup> Particularly for AKI, the refined consensus definitions have tended to be more sensitive and allow earlier diagnosis. Regardless of the cause and associated comorbidities, all AKI remains a diagnosis based on increases in serum creatinine or decreases in urine output. Although useful, these measures have limitations that underscore the need for newer methods to detect AKI and SA-AKI.

**Limitations of serum creatinine and urine output**

The initial limitation of a definition that relies on change in serum creatinine is establishing a baseline serum creatinine. No consensus method exists to establish pre-AKI baseline serum creatinine in the absence of previous values (recent or distant).<sup>46,47</sup> Furthermore, changes in serum creatinine are often delayed owing to renal reserve and the kinetics of AKI. Urine output is insensitive and is often measured accurately only in the ICU setting. Evidence from multiple retrospective cohort studies also suggests that the same stage of AKI diagnosed by serum creatinine and urine output may confer differential risk. Isolated urine output based AKI carries increased morbidity and mortality (compared with no AKI), but these risks are lower than those conferred by serum creatinine based AKI.<sup>48-50</sup>

**Emerging SA-AKI detection techniques**

Urinalysis and urine microscopy may aid identification of SA-AKI. Three observational studies evaluated a urine micros-

copy score specifically in a cohort with SA-AKI (box 2).<sup>51-53</sup> SA-AKI shows more renal tubule epithelial cells and cast elements compared with non-septic AKI. In a small prospective, two center study of 83 patients, 43 with SA-AKI, a urinalysis score above 3 was predictive of severe AKI and was highly correlated with biomarkers of tubular injury.<sup>53</sup> Separately, a single center observational study of 423 patients with sepsis showed that new albuminuria was associated with an odds ratio of 1.87 (1.21 to 2.89) for developing SA-AKI, even after adjustment for baseline GFR, severity of critical illness, and exposure to nephrotoxins.<sup>54</sup> These data have yet to be prospectively replicated, but routine dipstick albuminuria has also been shown to be independently associated with lower rates of recovery from AKI.<sup>55</sup>

Most validated AKI risk scores focus on AKI after cardiac surgery or in a general hospital population.<sup>37-56-64</sup> No widely accepted risk score has been validated for risk of SA-AKI, and only one validated score predicts mortality in patients with SA-AKI who need renal replacement therapy (RRT).<sup>65</sup> The performances of non-specific AKI risk scores and other critical illness scores have been disappointing in patients with SA-AKI.<sup>66</sup> A retrospective study investigated the performance of several risk scores (Liano,<sup>63</sup> Simplified Acute Physiology Score II,<sup>66</sup> PICARD,<sup>37</sup> and Demirjan<sup>64</sup>) to detect SA-AKI in 343 patients requiring continuous RRT, but no score provided an area under the curve (AUC) greater than 0.70.<sup>67</sup> A multicenter study of 214 pediatric ICU patients with sepsis assessed the ability of a renal angina index (RAI) and other novel biomarkers to predict SA-AKI.<sup>68</sup> The RAI is a tiered score in which patients are assigned points based on their risk of AKI (due to comorbidities) as well as their degree of injury (change in creatinine clearance). The RAI provided an AUC of 0.80 (0.75 to 0.86) for KDIGO stage 2 or 3 on ICU day 3 and outperformed several biomarkers including neutrophil gelatinase associated lipocalin (NGAL). When RAI was combined with NGAL and other biomarkers, either individually or in pairs, the predictive performance for stage 2 or 3 AKI was significantly improved (AUC 0.84-0.88;  $P < 0.05$ ).<sup>68</sup>

Several serum biomarkers that have been shown to be inversely correlated with GFR may provide an advantage in detecting AKI in patients with sepsis. Proenkephalin and cystatin C are both highly associated with AKI and GFR and increase before serum creatinine in critically ill patients with sepsis (table 3).<sup>70-72</sup> One study evaluated the ability of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein-7 (TIMP2\*IGFBP7), markers of cell cycle arrest, to predict the development of stage 2 or 3 AKI in 232 high risk critically ill patients with sepsis. Forty (17%) patients developed stage 2 or 3 AKI, with TIMP2\*IGFBP7 providing an AUC of 0.84. The biomarker performed similarly regardless of severity of illness (SOFA score), and a cutoff of 1.0 provided a sensitivity of 77.5% and a specificity of 75% for the development of severe AKI.<sup>73</sup>

NGAL, which is commercially available in several countries, is up regulated along the renal tubule in the setting of ischemic injury, nephrotoxins, and inflammation. Data have been inconsistent in SA-AKI.<sup>74,75</sup> Multiple studies have shown that plasma NGAL is elevated in

**Table 3 | Biomarkers used for detection of acute kidney injury (AKI)**

Type of biomarker	Subclass of biomarker	Examples of biomarkers	Comments
Functional biomarker of AKI	Biochemical markers of glomerular filtration/ function	Serum creatinine, serum cystatin c, proenkephalin, visible fluorescent injectates <sup>69</sup>	Serum creatinine remains the gold standard, but other novel markers of glomerular function have been shown to rise earlier and with the same accuracy as creatinine. Injectables may represent the future of GFR measurement, with the injection of small dextrans providing rapid determination of GFR at the bedside. May be elevated in the setting of CKD
	Global assessment of nephron function	Urine output	Urine output detects less severe AKI compared with creatinine and can be affected by diuretics and other drugs. Generally needs indwelling catheter for reliable measurement, with measurements being less frequent outside ICU
	Global assessment of nephron capacity	Furosemide stress test, renal reserve testing	These tests interrogate the kidney's capacity for increased function via protein loading (hyperfiltration) or diuretic responsiveness but are not validated in the setting of sepsis
Damage/injury biomarkers	Global assessment of nephron injury	Urinalysis	Urinalysis can detect injury along the entire nephron (from glomerulus to tubules); although scoring systems exist (box 2), none has been widely validated in any setting of AKI.
	Biochemical biomarkers of renal tubular injury	Urinary NGAL, urinary KIM-1, soluble FAS	These remain an area of intense AKI research but have yet to be widely validated in the setting of human AKI
AKI risk biomarkers	Biochemical biomarkers of AKI risk	TIMP2*IGFBP7, plasma NGAL	Increasingly available for clinical use, these markers quantify an individual patient's risk for impending AKI
	Biomarkers of AKI risk	Electronic alerts, electronic risk algorithms	Although not specific to SA-AKI, several alerts have shown their ability to predict the impending development of sepsis and AKI separately. Using these alerts in concert with biochemical biomarkers may help to enrich SA-AKI detection and risk stratification

CKD=chronic kidney disease; GFR=glomerular filtration rate; ICU=intensive care unit; IGFBP7=insulin like growth factor binding protein-7; KIM-1=kidney injury molecule-1; NGAL=neutrophil gelatinase associated lipocalin; SA-AKI=sepsis associated acute kidney injury; TIMP2=tissue inhibitor of metalloproteinase-2.

patients with sepsis even in the absence of AKI.<sup>76</sup> Other studies have shown that elevations of plasma NGAL even in the absence of elevated serum creatinine can identify critically ill patients at risk for severe AKI and inpatient mortality.<sup>77,78</sup> Plasma NGAL has also been shown to be elevated in sepsis regardless of the presence of AKI, but a higher cutoff threshold (454 ng/mL) provided a sensitivity of 72% and specificity of 74% for the detection of AKI.<sup>79</sup> Urinary NGAL and urine kidney injury molecule-1 (KIM-1) have been used to try to quantify renal tubular damage in SA-AKI; although some association has been shown, large scale studies have not validated these findings.<sup>80</sup>

Several other novel biomarkers have been investigated in the setting of SA-AKI, and table 3 summarizes some of these findings and uses the framework from figure 1.<sup>81</sup> Finally, an effort is ongoing to take a step back from biochemical measures such as NGAL or TIMP2\*IGFBP7 and use real time data from the electronic health record to identify patients with either sepsis or AKI, and we anticipate that automated alerts for these patients will be combined with biochemical biomarker testing to improve risk stratification and case detection for SA-AKI. We anticipate that electronic risk score and biochemical biomarkers will be incorporated into standard of care over the next decade.<sup>82-84</sup>

### Pathobiology of SA-AKI

Recent advances in sepsis related organ dysfunction have enhanced our knowledge of the pathobiology of SA-AKI.<sup>85-88</sup> Renal hypotension and associated ischemia had been believed to be the primary lesion in SA-AKI, but more recently several animal models have shown that although tubular cell injury and expression of markers such as KIM-1 are common, inflammation and apoptosis are also playing a role.<sup>89,90</sup> These data fit with the evolving

view of multifocal organ injury including macrovascular and microvascular dysfunction and immunologic and autonomic dysregulation. In depth discussions of these pathways are beyond the scope of this review, but we will highlight the animal models that elucidate these pathways. Table 4 summarizes the four most common experimental models, as well as their strengths and limitations.

In a placebo controlled ovine model of SA-AKI following direct infusion of bacteria, renal histology showed patchy and focal changes with limited tubular injury.<sup>89</sup> Animals with SA-AKI actually had higher renal blood flow (RBF) than controls. This differs from the decreased RBF in humans with SA-AKI, measured by phase contrast magnetic resonance imaging, thermolodulation, and renal Doppler.<sup>92-94</sup> This disconnect between human and animal data underscores the limitations of our understanding of the relation between RBF and renal function and has led some people to call for an increased role of renal biopsy in the setting of human sepsis. In the US, the National Institutes of Health have recently begun the Kidney Precision Medicine Project, which aims to ethically obtain and evaluate kidney biopsies from patients with AKI to create a kidney tissue atlas, define disease phenotypes, and identify critical cells, pathways, and targets for novel therapies in the setting of sepsis and other forms of AKI; thus we anticipate advancement of our knowledge in SA-AKI in the near future.<sup>95</sup>

Disturbances in microcirculatory oxygen delivery may include both decreased flow and diffusion limitation in the setting of organ edema and inflammation.<sup>96</sup> Although the exact ramifications of altered microcirculation are incompletely understood, sepsis increases expression of inflammatory cytokines and leukocyte activity, which may result in capillary plugging and micro-thrombi. This leads to production of reactive oxygen species and induction of nitric oxide synthase, which may further damage the endothelial barrier and the glycocalyx,<sup>97-99</sup> leading

AKI model	Animals	Model description	Strengths/limitations
<b>Non-surgical</b>			
Direct endotoxin administration	Mammalian but predominantly murine	Purified endotoxin (lipopolysaccharide from outer membrane of Gram negative bacteria) is directly injected intraperitoneally or intravenously	Easier and cheaper than surgical models, but animals often need high dose of lipopolysaccharide to produce shock. Lipopolysaccharide concentrations in these models may be 10-200 times the concentrations found in human sepsis. Additionally, cardiovascular response shows earlier cytokine release and hypodynamic cardiovascular response than human sepsis. Value of this model has been questioned despite its convenience and reproducibility <sup>91</sup>
Direct bacterial administration	All mammals but frequently used in larger mammals (porcine and ovine) and also in zebrafish	Live bacteria can be delivered to host (intravenously, intraperitoneally, subcutaneously, or directly into organ (eg, lung)). Can use Gram negative and Gram positive bacteria	Like lipopolysaccharide model, it allows for varied route of infection as well as varied administration (bolus v continuous). This allows for reproducibility in follow-up studies, but host response to whole microbe can be variable (as with lipopolysaccharide). Additionally, sudden administration of single strain does not model all forms of human sepsis
<b>Surgical</b>			
Cecal ligation and puncture or intra-abdominal fecal implantation	Mammalian but predominantly murine	Peritoneal cavity is accessed and either cecum is perforated or stool is directly implanted resulting in abdominal sepsis. Similar model uses colon ascendens stent, which allows feces to leak from bowel to peritoneum	Easy, but does not mimic non-abdominal infectious sources. Sepsis is often polymicrobial, which may be case in humans, but large degree of variability exists in severity of sepsis and resultant acute kidney injury. This variability stems from differences in surgical techniques as well. Can be enhanced with biotelemetry
Bacterial implantation models	Mammalian but predominantly murine	Bacterial impregnated substance (most commonly fibrin clot) is implanted in desired locations (intraperitoneal, intravascular).	Replicates hyperdynamic response of human sepsis, but single organism has same limitations as direct bacterial administration. Dose and timing can be altered to maximize effects, but whether it justifies increased costs of surgical procedure (compared with direct bacterial administration) remains unclear

to both structural and functional changes in the setting of SA-AKI (fig 1).

These structural and functional changes may not work in sync. In an ovine model, no association was seen between early SA-AKI and histopathologic lesions on renal biopsy.<sup>90</sup> Septic animals (n=10) had increased mesangial expansion on electron microscopy compared with non-septic animals, but no significant structural disturbances were found compared with controls (n=5).<sup>90</sup> Although surprising, these findings may be valid given that larger animals better mimic the human cardiovascular response in sepsis.<sup>90-100-102</sup> More specifically, ovine autoregulatory responses in untreated shock and shock treated with vasoactive drugs are similar to those in human kidneys with AKI.<sup>100-101-103</sup> Increased investigation of the interplay of the inflammatory cytokines and infiltrating cells and apoptosis will further our knowledge on the effect of these factors on the renal histology and the macrocirculation and microcirculation.

#### Prevention and medical treatment

In this section, we will explore prophylactic and therapeutic interventions in the setting of developing and established SA-AKI. This will include considerations in the general care of the patient with sepsis that have been shown to affect the incidence or severity of AKI, as well as therapies specifically targeted to the injured kidney.

#### Resuscitation

Inflammation in sepsis leads to endothelial failure and consequent loss of veno-motor tone and barrier function. The resultant reduction in the mean systemic pressure and relative hypovolemic state, paired with decreased systemic vascular resistance, results in hypotension.<sup>8</sup> Prompt resuscitation of the circulation with administration of intravenous fluids is a key component of sepsis

management.<sup>104-106</sup> However, excessive administration and accumulation of fluids in an attempt to treat hypotension or oliguria after AKI is common and harmful.

In a randomized trial of a conservative versus a liberal fluid strategy in 1000 patients with acute respiratory distress syndrome (ARDS), the patients in the conservative fluid arm not only had more ventilator-free and ICU-free days but had a non-significant trend toward less AKI needing RRT than those in the liberal fluid arm (10% v 14%; P=0.06).<sup>107</sup> Additional analysis of this trial and other studies of fluid management have also shown the harms of excess fluid during and after the development of AKI.<sup>108-110</sup> Postulated mechanisms driving this phenomenon include cardiac overload with falling cardiac output, resultant renal venous hypertension, increasing resistance, and decreased renal perfusion pressures.

Separately, edema driven rises in intra-abdominal pressure may inhibit renal venous drainage, further exacerbating the elevation of renal vascular pressure.<sup>43-111-112</sup> High quality resuscitation care of the patient with sepsis includes an initial modest bolus of resuscitation fluid (30 mL/kg within the first three hours) followed by a frequent assessment with dynamic measures of fluid responsiveness to determine whether additional fluids or vasoactive drugs are indicated.<sup>113</sup> Over-resuscitation and under-resuscitation have both been associated with adverse outcomes in the setting of shock. Recent studies have shown that protocolized resuscitation strategies did not improve outcomes, but a minimal degree of resuscitation is needed to mitigate the risk of adverse outcomes. Finally, clear evidence shows that in addition to the risks of under-resuscitation, in the setting of AKI, volume overload from aggressive over-resuscitation is also harmful, creating a J or U shaped curve for resuscitation and mortality.<sup>104-106-114</sup>

### Selection of resuscitation fluids

An equally important emerging literature suggests that the type of resuscitation fluid may affect sepsis and SA-AKI outcomes. Perhaps the most definitive and consistent finding pertains to the use of hyperoncotic starch solutions. These solutions should be avoided in sepsis and in all other patients at risk for AKI, as multiple studies have shown that hydroxyethyl starches are associated with increased risk of AKI and need for RRT compared with a variety of crystalloid solutions.<sup>115-119</sup>

Other researchers have studied the effect of crystalloid solutions versus other, non-hyperoncotic starch colloids such as albumin in the setting of sepsis with risk for SA-AKI. In the SAFE trial, 1218 patients with severe sepsis were prospectively randomized to receive either albumin (n=603) or saline (n=615). Patients receiving albumin had higher central venous pressures over the first three days and a non-significant trend to decreased mortality but no difference in RRT rates across the two groups (18.7% v 18.2%; P=0.98).<sup>120</sup> Subsequent studies of albumin have also found modest improvements in outcomes such as hemodynamic variables but have not shown improvements in AKI or mortality.<sup>121-124</sup> This high quality literature has not shown significant benefit to albumin containing regimens, so their use cannot be recommended over less costly crystalloid solutions.

More recently, multiple studies have compared outcomes between balanced and hyperchloremic crystalloid solutions, with some but not all suggesting that hyperchloremic solutions may be associated with increased AKI and mortality.<sup>125-128</sup> One retrospective cohort of 60 734 adults with septic shock found that patients receiving exclusively isotonic saline had higher inpatient mortality than those who were co-administered balanced solutions (20.2% v 17.7%; P<0.001).<sup>124</sup> Two large prospective trials have recently added to this literature.<sup>129 130</sup> A pragmatic, cluster randomized, multiple crossover trial at a single center with 15 802 patients showed no difference in the primary endpoint of hospital-free days but did show that balanced solutions were associated with a lower rate of a composite endpoint of major adverse kidney events (all cause mortality, need for RRT, and doubling of serum creatinine from baseline) within 30 days (14.3% v 15.4%; P=0.01).<sup>129</sup> Subset analysis of patients with sepsis also showed that balanced crystalloids were associated with an even greater reduction in major adverse kidney events, as well as the 30 day mortality component of the composite endpoint.<sup>130</sup> Additionally, among the patients who derived the most benefit in these trials were those who had developed some degree of hyperchloremia and kidney injury before enrollment in the study.<sup>129 130</sup> Although the relatively low volumes of resuscitation fluid (approximately 2 L over the first three days) in these trials likely differ from practice, they add to a mounting body of data suggesting that balanced crystalloid solutions may improve renal outcomes and survivorship in non-selected and septic critically ill patients.

### Vasoactive drugs

The selection of the ideal vasopressor in the setting of shock (regardless of AKI status) has been the source of

several large scale multicenter trials.<sup>103 131-135</sup> In the setting of SA-AKI, traditional agents such as norepinephrine (noradrenaline), epinephrine, vasopressin, and dopamine, as well as more novel agents such as angiotensin II and levosimendan, have been investigated.

Norepinephrine has been a mainstay of treatment of septic shock, showing the ability to increase mean arterial pressure (MAP) and improve renal perfusion. Norepinephrine has been generally regarded as the first line agent for septic shock on the basis of many clinical trials suggesting either better outcomes or fewer adverse events than with other vasoactives.<sup>131 136-139</sup> However, ovine data suggesting that norepinephrine may exacerbate renal medullary hypoxia as the kidney attempts to preferentially shunt blood flow to the cortex in SA-AKI have led some researchers to revisit other agents in the setting of septic shock and SA-AKI.<sup>100 140</sup> Vasopressin is of particular interest, as the Vasopressin and Septic Shock Trial (VASST) comparing norepinephrine with vasopressin showed similar outcomes and no increased adverse events across all study patients and a survival benefit in subgroup analysis of patients with less severe shock.<sup>141</sup>

The VANISH trial was a prospective, double blind, randomized clinical trial with a two by two (vasopressin or norepinephrine, hydrocortisone or placebo) factorial design in the setting of septic shock.<sup>131</sup> Patients were randomly allocated to vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n=101), vasopressin and placebo (n=104), norepinephrine and hydrocortisone (n=101), or norepinephrine and placebo (n=103). No difference by vasopressor was seen in the development of AKI in patients who survived (vasopressin group 57.0%, norepinephrine group 59.2%), in AKI-free days among patients who died in the hospital (vasopressin group 33.3%, norepinephrine group 29.4%), or in serious adverse events. These data may suggest that vasopressin is a viable first line alternative to norepinephrine.

However, not all vasoactive agents have performed so favorably. During norepinephrine shortages from 2008 to 2013 ( $\geq 20\%$  decrease from baseline usage), a retrospective cohort study of 26 US hospitals showed an increase in inpatient mortality to 39.6% during the shortage compared with 35.9% with typical norepinephrine use, representing an odds ratio of 1.15 (1.01 to 1.30; P=0.03).<sup>133</sup> Phenylephrine and dopamine were the most common agents used in place of norepinephrine during the shortage. Paired with other trial data, many people have suggested that phenylephrine and, to an even greater extent, dopamine should be avoided as first line treatment of septic shock.<sup>132 136 138 139</sup>

Angiotensin II, a hormone in the renin-angiotensin-aldosterone system, is a novel agent recently investigated in the setting of shock.<sup>103 135</sup> In the Angiotensin II for the Treatment of High Output Shock (ATHOS-3) trial, 344 patients with vasodilatory shock (259 of whom had sepsis) who were receiving 0.2  $\mu\text{g}/\text{kg}/\text{min}$  (or equivalent) of a vasopressor were randomized to receive either angiotensin II or placebo.<sup>135</sup> Angiotensin II led to a significant increase in the MAP from baseline within the first three hours of infusion. MAPs were increased in 69.9% of patients in the angiotensin II arm compared with

23.4% of the placebo arm (odds ratio 7.95, 4.76 to 13.3;  $P < 0.001$ ). An improvement was also seen in the cardiovascular SOFA score, with scores decreasing a mean of  $-1.75$  points for patients in the angiotensin II arm compared with  $-1.28$  in the placebo arm ( $P = 0.01$ ). No difference was seen in inpatient mortality.<sup>135</sup> A small subgroup analysis of patients treated with RRT showed that those receiving angiotensin II needed less RRT, were more likely to survive through day 28 (53% v 30%;  $P = 0.012$ ), and were more likely to be alive and RRT free by day 7 (38% v 15%;  $P = 0.037$ ) compared with placebo. If these results are validated in larger cohorts, angiotensin II may represent a novel treatment for SA-AKI.<sup>103</sup>

Levosimendan is a calcium sensitizing drug with inotropic properties that has been used to treat decompensated heart failure, with small studies showing its ability to increase creatinine clearance and urine output compared with dobutamine.<sup>134 142</sup> Unfortunately, in a large scale, double blind, randomized trial investigating the addition of levosimendan (compared with placebo) in adults with sepsis (MAKE-28), no difference was seen in renal outcomes.<sup>134</sup> Thus, no data support its use in the treatment of SA-AKI.

Norepinephrine and vasopressin remain consensus first line agents for the treatment of septic shock, although treatment should be tailored to the individual patient. Although previous studies have shown that MAP targets higher than the 65 mm Hg recommended in sepsis guidelines decreased the rate of RRT in patients with hypertension, this did not translate to improved survival.<sup>143</sup> A higher MAP should be targeted only with active surveillance to evaluate for adverse effects from these potentially harmful agents.

### Mechanical ventilation

Critically ill patients with sepsis and septic shock often need mechanical ventilation with positive pressure (PPV) to provide support with oxygenation, ventilation, and airway protection in the setting of organ failure. PPV has long been known to have potentially deleterious effects on kidney perfusion and function.<sup>144</sup> More recently, a high quality systematic review and meta-analysis of studies reporting a relation between the use of invasive mechanical ventilation and the subsequent onset of AKI or comparing high and low tidal or positive end-expiratory pressure with the development of AKI found that the pooled odds ratio for development of AKI in the setting of mechanical ventilation was 3.16 (2.32 to 4.28), with similar findings in a subset that allowed multivariate analysis (3.48, 1.85 to 6.92).<sup>145</sup>

Work from animal models and clinical trials suggest that the mechanism is likely multifactorial. PPV increases intrathoracic pressure, reducing venous return, cardiac output, and renal perfusion.<sup>146-149</sup> This proposed mechanical mechanism is supported by several landmark clinical trials of ARDS. In a randomized controlled trial (RCT) of low tidal volume ventilation in ARDS, renal failure was seen less often in patients in the lower tidal volume intervention arm.<sup>150</sup> A more recent RCT of lung recruitment and titrated positive end-expiratory pressure (PEEP) did not report renal outcomes but noted a higher

incidence of need to increase vasoactive drugs (34.8% v 28.3%;  $P = 0.03$ ) in the recruitment and titrated PEEP group who had significantly higher plateau pressures.<sup>151</sup> However, these findings have not been consistent across all trials. An RCT of high versus low PEEP in 767 patients with ARDS did not show a difference in the rate of kidney injury, although the rates were low in both groups.<sup>152</sup> Furthermore, neither tidal volume nor PEEP had a modifying effect in a patient population with a low percentage of ARDS in the meta-analysis showing the threefold increased risk in AKI with mechanical ventilation.<sup>145</sup>

Mechanical ventilation probably also induces both neurohormonal and inflammatory changes that potentially increase the risk for AKI. Both mechanical ventilation and the ventilator strategy of permissive hypercapnia are known to induce sympathetic tone and the renin-angiotensin system, decreasing renal blood flow, redistributing renal flow to the medulla, and decreasing GFR.<sup>146-148</sup> Additionally, mechanical ventilation at any volume or pressure has consistently been shown to create a cascade of inflammation including multiple interleukins, tumor necrosis factor  $\alpha$ , and Fas ligand that may contribute to AKI.<sup>148</sup>

In aggregate, these mechanical, neurohormonal, and inflammatory effects of mechanical ventilation predispose to AKI. However, mechanical ventilation is unavoidable in many patients, and the ventilation strategy is largely dictated by the effect on oxygenation and overall survival. Whether a given strategy would potentially protect the kidney independent of and without sacrificing the support of the respiratory system is not clear. High tidal volumes and high intrathoracic pressures seen with recruitment maneuvers are likely best avoided. Permissive hypercapnia offers a potential benefit as a ventilator strategy, but it is not without its pitfalls, and clinicians must use this technique with caution in patients with right heart failure and increased intracranial pressures among others.<sup>147</sup> Finally, alternatives to invasive mechanical ventilation such as high flow oxygen systems, helmet non-invasive ventilation, and face mask non-invasive ventilation may confer a different risk, but insufficient data are available to recommend that one or the other modality should be used on the basis of consideration of the risk for AKI.<sup>145 153 154</sup>

### Drug treatment strategies for SA-AKI

The prophylactic use of diuretics, specifically furosemide, to prevent AKI has been shown to be unsuccessful and potentially harmful in critically ill patients.<sup>155 156</sup> Similarly, diuretics have not been shown to ameliorate or attenuate AKI once it is established.<sup>157</sup> Thus, the routine use of diuretics for the prevention or treatment of SA-AKI cannot be recommended. However, their utility in regulating and maintaining fluid balance fosters their continued use in the setting of critical illness despite their inability to improve renal outcomes.

In preclinical and small clinical studies, systemic administration of alkaline phosphatase has shown protection in SA-AKI.<sup>158-160</sup> Alkaline phosphatase has been thought to be effective through the direct dephosphorylation of endotoxin leading to attenuated inflammation and organ dysfunction and improved survival rates.

Table 5 | Therapies in sepsis associated acute kidney injury (SA-AKI): previous efforts and novel ongoing investigations

Agent	Mechanism of action	Comments
<b>Traditional agents that have not shown benefit in SA-AKI</b>		
Statins (hydroxymethyl glutaryl coenzyme A reductase inhibitors)	Anti-inflammatory properties, cardiovascular risk reduction, pleiotropic effects	Did not reduce AKI risk in patient with pneumonia associated sepsis <sup>166</sup> ; meta-analysis of seven RCTs showed no effect on mortality across statin agents and several dosing ranges <sup>167</sup>
N-acetyl-cysteine	Potent scavenger of reactive oxygen species, improves glutathione stores	Wealth of animal data support its ability to prevent AKI in sepsis models, <sup>168,169</sup> but no human data support its use in SA-AKI or other AKI settings <sup>170,171</sup>
Tight glucose control	Theoretically decreases oxidative stress and endothelial dysfunction	Large scale prospective RCT of surgical ICU patients showed 41% reduction in AKI requiring RRT with blood sugar between 80 and 110 mg/dL, <sup>172</sup> but this effect was not validated in several follow-up studies including investigation specifically in patients with sepsis (although this was a 2x2 design that included pentastarch). <sup>115</sup> Follow-up studies in ICU patients showed no renal effects and perhaps signal for increased mortality with blood sugar 81-108 mg/dL <sup>173</sup>
Erythropoietin	Hematologic growth factor with anti-inflammatory and anti-apoptotic effects	Most investigation of erythropoietin and AKI has occurred in cardiac surgery patients, but two large trials investigating its use in mixed ICU populations failed to show improvement in AKI outcomes. <sup>174,175</sup> However, <20% of patients in both these studies had sepsis/septic shock.
Steroids (glucocorticoids and mineralocorticoids)	Classes of hormones that work to control carbohydrate and protein metabolism (glucocorticoids) and control electrolyte and fluid balance (mineralocorticoid) with anti-inflammatory properties	Role of steroids remains controversial in setting of sepsis, but two recent studies showed limited effects on SA-AKI. APROCCHSS trial, which looked at hydrocortisone and fludrocortisone, showed no difference in need for RRT between patients who did and did not receive steroids (27% v 28.1%). <sup>176</sup> ADRENAL trial showed no difference in use of RRT (30.6% in hydrocortisone group; 32.7% in placebo group; P=0.18), and no difference in number of days spent alive and RRT free (P=0.29) <sup>177</sup>
<b>Promising novel agents that need further investigation</b>		
Alkaline phosphatase	Will dephosphorylate endotoxins, perhaps leading to weakened inflammatory response	In a prospective, randomized, double blind, placebo controlled trial (n=36), intravenous infusion of alkaline phosphatase improved endogenous creatinine clearance and was associated with lower biomarkers of renal tubular injury, with no reduction in RRT rates. <sup>178</sup> A recent multicenter international trial was not successful in replicating these improved AKI rates but did show improved 28 day mortality in setting of SA-AKI <sup>161</sup>
Thiamine	Thiamine deficiency is associated with anaerobic metabolism and increased lactates. Ensuring thiamine repletion may improve mitochondrial function in setting of sepsis	In secondary analysis of a single center randomized, double blind, placebo controlled trial of 70 patients with septic shock, those randomized to receive intravenous thiamine (200 mg twice a day for 7 days) had less severe AKI and fewer patients receiving RRT <sup>179</sup>

AKI=acute kidney injury; ICU=intensive care unit; RCT=randomized controlled trial; RRT=renal replacement therapy.

A recent international, randomized, double blind, placebo controlled, dose finding adaptive phase IIa/IIb study included 301 adults with SA-AKI.<sup>161</sup> In the dose finding portion of the trial, 120 patients were randomized to receive recombinant alkaline phosphatase in a dose of 0.4, 0.8, or 1.6 mg/kg of the drug or placebo, with 1.6 mg/kg being determined to be the optimal dose. Then 82 patients received 1.6 mg/kg of alkaline phosphatase compared with 86 receiving placebo. Although the study did not show a decrease in the primary endpoint of time corrected AUC of creatinine clearance for days 1 to 7, it did show decreased mortality in patients receiving alkaline phosphatase. More stage 3 AKI occurred in patients receiving alkaline phosphatase (11/111; 9.9%) than in those receiving placebo (5/116; 4.3%).<sup>161</sup> However, given the decreased 28 day mortality (17.4% in patients receiving 1.6 mg/kg compared with 29.5% of those in the placebo group), some possibility exists that although it is not a treatment for SA-AKI, recombinant alkaline phosphatase may play a role in the treatment of sepsis itself.

A large body of preclinical work has investigated several pathways to potentially intervene and prevent or treat SA-AKI, and although this work has focused on molecules such as the caspase and interleukin inhibitors, to date it has not translated into human investigations of SA-AKI.<sup>162-165</sup> Table 5 summarizes several clinical trials that have investigated novel and traditional agents in the setting of SA-AKI. Additionally, table 6 provides information about clinical trials found on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) that are actively recruiting patients with SA-AKI.

#### Renal replacement therapy

Much of the data around the use of RRT in the setting of SA-AKI are informed by larger trials that have investigated

dose, timing, and modality of RRT in the broader population of ICU patients needing RRT.<sup>185-189</sup> However, several investigations have focused on patients specifically with SA-AKI, and these are discussed below and summarized in table 7.

The sepsis and SA-AKI specific data around the timing of RRT point to potential harm with earlier initiation. In a recent multicenter, randomized controlled trial, patients with early stage septic shock who had RIFLE-failure AKI (table 1) were randomized to receive RRT within 12 hours of meeting entry criteria (early) or after a 48 hour delay (if possible and if needed—delayed arm).<sup>190</sup> In this French trial, which was stopped early for futility, 58% (138/239) of the early group and 54% (128/238) of the delayed group had died (P=0.38). Additionally, 93 (38%) patients in the delayed arm never needed RRT. In addition to this SA-AKI specific large scale study, evidence suggests that starting RRT early in patients with sepsis may not be beneficial.

In a prospective, randomized, multicenter French trial, 80 patients received either 96 hours of hemofiltration (25 mL/kg/h) or conservative management within 24 hours of any sepsis induced organ failure (including non-renal organs, with a baseline serum creatinine of 188 μmol/L). This early start, sometimes in the absence of SA-AKI, led to increased adverse outcomes including worsening organ failure.<sup>191</sup> Then, in a recent post hoc analysis of the AKIKI (Artificial Kidney Initiation in Kidney Injury) trial in 174 patients in each arm with septic shock, no difference in 60 day mortality was seen between the early and delayed arms. A significant increase was seen in renal recovery, as measured by urine output, in patients in the delayed arm.<sup>197</sup> These findings, suggesting benefits of delayed RRT, were not replicated by a recent trial

**Table 6 | Trials that are actively recruiting patients with sepsis associated acute kidney injury (SA-AKI) as of autumn 2018**

Agent/intervention	Mechanism of action	Study population	Study design
Reltecomod <sup>180</sup>	Peptide that binds CD28 co-stimulatory receptor and modulates immune response	Adult ICU patients (n=120) with underlying abdominal infection and stage 2/3 AKI	Phase II randomized, placebo controlled, multicenter study assessing ability of reltecomod to achieve recovery from abdominal SA-AKI
Adsorptive filter <sup>181</sup>	Use of PrismafleX eXeed (Hospal) using ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface	Adult ICU patients (n=110) with SA-AKI requiring dialysis	Prospective, multicenter, randomized trial assessing cytokine concentrations and patient outcomes using adsorptive filter
Balanced crystalloids versus 0.9% normal saline <sup>182</sup>	Balanced solutions (Ringer's acetate) have been shown to improve AKI and MAKE outcomes in ICU patients	Adult ICU patients (n=236) with sepsis	Prospective, double blind, single center, parallel assignment trial of normal saline or Ringer's acetate to determine incidence and severity of AKI in patients with sepsis
L-carnitine <sup>183</sup>	Has been shown to enhance glucose and lactate oxidation and improve smooth muscle and cardiac function in setting of critical illness	Adult ICU patients (n=272) with sepsis/septic shock	Prospective, double blind, placebo controlled, multicenter trial investigating effect of L-carnitine on short and long term outcomes in patients with septic shock
Peripheral arterial tonometry/renal plasma flow/blood pressure measurement and renal function assessment <sup>184</sup>	Measurement of residual kidney function in pediatric patients and young adults with SA-AKI to determine effect on host and long term development of kidney disease	Pediatric and young adult (<24 years old) (n=45) with severe sepsis	Prospective, cross sectional, control-cohort study. Patients with SA-AKI will be monitored after discharge for formal measurement of glomerular filtration rate, renal plasma flow, and peripheral arterial tonometry to determine long term effect of SA-AKI on renal function

AKI=acute kidney injury; ICU=intensive care unit; MAKE=major adverse kidney event.

investigating timing of RRT in ICU patients (32% with severe sepsis).<sup>186</sup> One large scale, non-SA-AKI specific trial is recruiting participants to further investigate the optimal timing of RRT.<sup>198</sup>

Dose of RRT has been extensively studied in the setting of SA-AKI, with several studies showing no benefit to the increased dosing of RRT (table 7).<sup>193-196</sup> Much of the dosing guidelines stem from two large scale multicenter randomized controlled trials; however, these two trials were not exclusively done in the setting of SA-AKI. The Veterans Administration-NIH Acute Renal Failure Trial Network enrolled 1055 patients, 579 (54.9%) of whom had sepsis; the Randomized Evaluation of Normal versus Augmented Level (RENAL) Replacement Therapy Trial studied 1465 patients, 723 (49.3%) of whom had severe sepsis. Their combined results have shown that if continuous RRT is needed, the recommended delivered dose should be 20-25 mL/kg/h, with close attention being paid to all drug dosing.<sup>187-188</sup> Clinicians should remember that the delivered dose is often lower than the prescribed dose, so in the setting of SA-AKI the dosing of continuous RRT should be at least at the 30-35 mL/kg/h range to ensure adequate delivery.<sup>187</sup> Finally, as these two large scale studies and smaller ones specific to SA-AKI have shown, higher doses (for example, 70 mL/kg/h) of continuous RRT do not improve patients' survival.<sup>187-188-194</sup>

Limited data suggest a benefit with any specific RRT modality. An RCT randomized 77 patients with AKI needing continuous RRT to receive either 35 mL/kg/h of continuous veno-venous hemofiltration or continuous veno-venous hemodialysis (63 (82%) of whom had sepsis).<sup>189</sup> The results showed no difference in renal recovery or 60 day mortality (56% v 55%).<sup>189</sup> Finally, no data support the use of intermittent hemodialysis over continuous RRT (or vice versa) in the setting of SA-AKI. Although several studies have investigated this question, meta-analyses and large RCTs have shown no difference.<sup>199-201</sup> Thus, physicians should start an RRT modality that they are comfortable with and that can achieve the guideline recommended dose of a Kt/V of 3.9 per week in the setting of intermittent dialysis and a delivered dose of 20-25 mL/kg/h in continuous RRT, as well as one that will achieve the desired clearance and ultrafiltration for each specific patient.<sup>7</sup>

The use of extracorporeal therapies to remove circulating endotoxin has been studied in the setting of septic shock. In several, predominantly Japanese, trials using polymyxin B hemoperfusion, these techniques have shown a mortality benefit.<sup>202</sup> Similarly, the EUPHAS (Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock) trial showed that patients randomized to receive two sessions of polymyxin B hemoperfusion (n=34) (compared with conventional therapy, n=30) had improved MAPs, lower critical illness scores, and lower 28 day mortality (32% v 53%; P=0.01). Importantly, not all of these patients had AKI or the need for RRT (n=19), as enrollment was based solely on the presence of septic shock.<sup>203</sup> In a follow-up study (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock; EUPHRATES), 450 eligible patient with documented endotoxemia and shock were enrolled and randomized to potentially receive two hemoperfusion treatments 24 hours apart (or placebo).<sup>204</sup> However, polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days, with 37.7% mortality in the treatment group and 35.5% mortality in the sham cohort (P=0.49). In fact, 10.8% of the treatment group had a worsening of their sepsis compared with 9.1% of the sham group.<sup>204</sup> Not enough evidence exists to recommend the use of hemoperfusion in the setting of septic shock or SA-AKI.<sup>24</sup>

#### Renal recovery and other long term outcomes

Recently, several reviews on renal recovery following AKI have been written, but no formally accepted definition of renal recovery exists.<sup>205-206</sup> For the past decade, several paradigms of AKI recovery have been hypothesized.<sup>24-207-208</sup> Proposed definitions range from total recovery (return of serum creatinine to baseline) to persistent AKI requiring RRT which becomes end stage renal disease (ESRD). Importantly, serum creatinine is not ideally suited to accurate measurement of renal reserve and may not be the best biomarker to quantify recovery, especially given the effect of muscle wasting on serum creatinine in critical illness. Most recently, ADQI proposed the concept of acute kidney disease, which separated out the first seven days of AKI (as per the KDIGO guidelines), calling this first week AKI but differentiating days 8-90 as

Table 7 | Summary of trials of timing and dose of renal replacement therapy (RRT) in sepsis associated acute kidney injury (SA-AKI)

Study	Indication for study	Comparison	No of patients with sepsis	Outcome and comments
Barbar et al <sup>190</sup>	Timing of RRT	Early stage septic shock patients with RIFLE-failure randomized to starting RRT immediately versus delayed start after 48 h if needed	All 488 patients had septic shock	This study, which was stopped early owing to futility, found no difference in 90 day mortality between patients in early arm (58%) and delayed strategy arm (54%). Additionally, 38% in delayed arm did not go on to receive RRT
Payen et al <sup>191</sup>	Timing of RRT	CVVH at 25 mL/kg/h versus usual care started within 24 h of first organ failure (including non-renal organs)	All 76 patients had sepsis; 37 randomized to CVVH and 39 to usual care arm	No improvement in outcomes with early continuous RRT. No difference in 28 day mortality (54% in CVVH group; 44% in usual care group; P=0.10)
Guadry et al <sup>192</sup>	Timing of RRT	Patients with acute tubular necrosis and stage 3 AKI randomized to immediate start of RRT versus delayed strategy requiring metabolic or respiratory derangement to start RRT	250/311 randomized to early start and 244/308 to delayed arm	No difference in 60 day survival (P=0.79). Patients randomized to delayed strategy were more likely to have increased urine output (1 L/day off diuretics or 2 L/day with diuretics). More patients in early initiation arm had infections (10% v 5%; P=0.03) and hypophosphatemia (22% v 15%; P=0.03)
Zhang et al <sup>193</sup>	Dose of RRT	Patients were randomly assigned to receive 50 or 85 mL/kg/h of hemofiltration	All 280 patients had sepsis, with 139 receiving 50 mL/kg/h and 141 receiving 85 mL/kg/h	No difference in 28 (57.4% v 58.3%) or 90 (59.6% v 63.3%) day survival in this cohort of patients with sepsis and a traditional indication for RRT (P>0.05 for both)
Joannes-Boyou et al (VOIRE) <sup>194</sup>	Dose of RRT	Patients with septic shock and at least a doubling of creatinine or 12 hours of oliguria randomized to receive 35 or 70 mL/kg/h	All 138 patients had septic shock, with 71 receiving 35 mL/kg/h and 66 receiving 70 mL/kg/h	No difference in 90 day mortality (56.1% v 50.7%; P=0.53), nor in ventilator, ICU, or hospital-free days at 90 days. Despite supplementation, more hypophosphatemia occurred in high dose group (P<0.01)
Park et al <sup>195</sup>	Dose of RRT	Patients with sepsis and at least a doubling of creatinine or 12 hours of oliguria randomized to receive 40 or 80 mL/kg/h	All 212 patient had sepsis, with 107 in 40 mL/kg/h arm and 105 in 80 mL/kg/h arm	No difference in 28 day mortality (64.5% v 65.7%; P=0.50) or 90 day mortality (74.8% v 78.1%; P=0.60). No difference in renal survival or cytokine concentrations between groups. No difference in electrolyte disturbances (potassium, phosphate, or magnesium) between groups
Chung et al (RESCUE) <sup>196</sup>	Dose of RRT	Burn patients with septic shock and AKI (<20 mL/h of urine for 24 h or increase in serum creatinine of 2.0 mg/dL in men or 1.5 mg/dL in women) randomized to receive 70 mL/kg/h of CVVH for 48 h or usual care	All 37 patients had sepsis, with 14 in control arm and 23 in 70 mL/kg/h arm	No difference in 28 day mortality (36% v 22%; P=0.45) or renal recovery among survivors. No difference in adverse events or electrolyte disturbances between groups

AKI=acute kidney injury; CVVH=continuous veno-venous hemofiltration; ICU=intensive care unit; RIFLE=risk, injury, failure, loss, end stage kidney disease.

acute kidney disease. This period serves as a framework for defining recovery and the potential progression to chronic kidney disease (CKD)/ESRD (fig 2).<sup>24</sup>

Given the lack of consensus for definitions of recovery from all cause AKI, data specific for SA-AKI recovery

are lacking. In a prospective observational cohort of 1753 critically ill patients with AKI, SA-AKI (n=833) was associated with increased risk of inpatient mortality but was also associated with a trend toward lower serum creatinine (median 106 (interquartile range 73-158) v 121 (88-184) μmol/L; P=0.01) and dependence on RRT (9% v 14%; P=0.052) at hospital discharge (n=920).<sup>31</sup> These differences were at least in part due to patients with non-septic AKI having more CKD before admission. This potential association between SA-AKI and improved renal function at the time of discharge is in contrast to a recent study defining patterns of recovery in 16 968 critically ill patients with stage 2 or 3 AKI.<sup>208</sup> Early reversal, defined as no longer meeting KDIGO stage 1 criteria within seven days, was subcategorized into sustained reversal, relapse with subsequent recovery, and relapse without recovery. Sepsis was associated with an increased risk of relapse compared with patients with early sustained reversal (odds ratio 1.34 (1.18 to 1.52); P<0.001).<sup>208</sup> A retrospective study also showed that diabetes makes recovery from SA-AKI less likely (41.1% in non-diabetic SA-AKI versus 60% in diabetic SA-AKI; P<0.001).<sup>209</sup> Given the size and observational nature of these datasets, further investigation of SA-AKI associated renal recovery is needed.

Evidence in settings other than sepsis shows that inpatients with AKI are more likely to be readmitted within 30-90 days.<sup>210-212</sup> Specific data on SA-AKI are lacking. However, Americans aged 50 years or older with a history of severe sepsis have been shown to be 2.5 times more likely to be readmitted to hospital for AKI within 90 days than comorbidity matched patients without sepsis.<sup>213</sup> In addition to readmission, some evidence




Fig 2 | Potential outcomes in the setting of acute kidney injury (AKI) and acute kidney disease (AKD). The figure shows the potential progression through the various stages of sepsis associated AKI (SA-AKI). AKI may occur over the first 7 days, when it can lead to persistent injury and become SA-AKD. During AKI, patients may have complete or partial recoveries, but some may have persistent injury without recovery. Longitudinally, this lack of recovery may become chronic kidney disease (CKD) or its most severe form end stage renal disease (ESRD). UOP=urine output; SCr=serum creatinine. Adapted and modified from Chawla et al 2017<sup>24</sup> and Forni et al 2017<sup>205</sup>

**Box 3 | Summary of management strategies for sepsis associated acute kidney injury (SA-AKI)****Screening and diagnosis**

- Closely monitor both urine output and serum creatinine in patients with sepsis
- Given limitations of urine output and serum creatinine, consider adoption of emerging risk scoring systems or serum biomarkers

**Supportive care**

- Use best practice strategies for patients with sepsis
  - Early administration of appropriate antibiotics
  - Achieve control or removal of source of infection
  - Adequate resuscitation with intravenous fluids while avoiding over-resuscitation
  - Use norepinephrine, vasopressin, or both as initial vasoactive drug(s)

**Avoid further kidney injury**

- Avoid potentially nephrotoxic drugs when possible
- Avoid potentially nephrotoxic contrast loads when possible
- Do not use hydroxyethyl starches

**Treatment of SA-AKI**

- Early initiation of renal replacement therapy (RRT) has not been shown to be superior to conventional timing of initiation of RRT
- The delivered dose of continuous RRT (CRRT) should be 20-25 mL/kg/h, which often requires dosing CRRT at 30-35 mL/kg/h
- Higher dose RRT (70-85 mL/kg/h) has not been shown to be superior to lower dose RRT (35-50 mL/kg/h)

points to increased risk for the development of post-AKI CKD, although limited supporting prospective data are available.<sup>214-218</sup> The Assessment, Serial Evaluation, and Subsequent Sequelae of AKI (ASSESS-AKI) study is following several hundred critically ill patients with and without SA-AKI to determine its impact on long term renal function in those who survive their index hospital admission.<sup>219</sup> In the future, biochemical (such as those discussed in table 3) or functional biomarkers such as renal functional reserve (for example, monitoring the kidney's ability to hyper-filter in the setting of a protein load)<sup>220</sup> may play a role in determining which patients with SA-AKI recover function and which progress to persistent AKI and eventual CKD and ESRD disease.

**QUESTIONS FOR FUTURE RESEARCH**

- Is there an ideal intravenous fluid and vasoactive drug to prevent or ameliorate early sepsis associated acute kidney injury (SA-AKI)?
- What is the best way to identify acute kidney injury at its earliest?
- Does removing endotoxin or endogenous cytokines via continuous renal replacement therapy or adsorption in the setting of SA-AKI have clinical utility?
- Can pairing biomarkers of renal injury with early interventions (therapeutic or pharmacologic) prevent SA-AKI?
- How do outcomes of SA-AKI differ from those of other forms of acute kidney injury?
- Does the paradigm of acute kidney disease accurately reflect the clinical course of SA-AKI?

**GLOSSARY OF ABBREVIATIONS**

ADQI—Acute Dialysis Quality Initiative
AKI—acute kidney injury
AKIN—Acute Kidney Injury Network
ARDS—acute respiratory distress syndrome
AUC—area under the curve
CKD—chronic kidney disease
ESRD—end stage renal disease
GFR—glomerular filtration rate
ICU—intensive care unit
IGFBP7—insulin-like growth factor binding protein-7
KDIGO—Kidney Disease: Improving Global Outcomes
KIM-1—kidney injury molecule-1
MAP—mean arterial pressure
NGAL—neutrophil gelatinase associated lipocalin
PEEP—positive end-expiratory pressure
PICARD—Program to Improve Care in Acute Renal Disease
PPV—positive pressure ventilation
RAI—renal angina index
RBF—renal blood flow
RCT—randomized controlled trial
RIFLE—risk, injury, failure, loss, end stage kidney disease
RRT—renal replacement therapy
SA-AKI—sepsis associated acute kidney injury
SIRS—systemic inflammatory response syndrome
TIMP2—tissue inhibitor of metalloproteinase-2

**Guidelines**

Both the KDIGO and National Institute for Health and Care Excellence (NICE) guidelines for AKI are high quality reviews, but neither focuses specifically on AKI in critically ill or septic patients.<sup>7,221</sup> One high quality multi-society guideline covers AKI in critically ill patients generally and offers guidance for several subsets of ICU patients, but does not cover SA-AKI specifically.<sup>222</sup>

**Conclusion**

Despite progress in our understanding of the factors that drive the pathobiology of SA-AKI, it remains a common and highly morbid complication of a common critical illness. Epidemiologic data suggest that population change and the continued march of intensive medical interventions are likely to increase its burden. Vigilance for risk factors for SA-AKI

**HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLE**

A 62 year old man with a previous history of postoperative sepsis associated acute kidney injury (SA-AKI) who had a hospital limited course of renal replacement therapy four years ago with the subsequent development of post-AKI chronic kidney disease accepted an invitation to review the manuscript as a patient reviewer for *The BMJ*. He reviewed the paper in its entirety, providing suggestions on which sections were most and least relevant to his personal history. As a result of this input, we emphasized the effect of SA-AKI on the potential development of chronic kidney disease as well as the limited treatment options in the setting of AKI. The patient asked us to emphasize the importance of continuing to work to discover and validate treatment options in the setting of acute kidney injury (and chronic kidney disease) and to remind people of the importance of nephrology care in the setting of kidney disease.

risks is essential so that preventive strategies may be implemented. We must consider how the choices we make with the fundamental elements of our critical care practice (fluid, vasoactive, and ventilator management) affect the kidneys. Patients at risk for SA-AKI should be screened aggressively to allow early identification and implementation of a care plan (box 3), and further study is needed to allow us to understand the factors involved in and the likelihood of renal recovery and future risk after an episode of SA-AKI.

However, even perfect implementation of current best practice is unlikely to significantly ameliorate the burden of SA-AKI. Novel translational animal models, the wealth of data available in modern electronic health records, and a myriad novel clinical biomarkers present a tremendous opportunity to refine our understanding of SA-AKI, and may allow us to set a new course for prevention, treatment, and renal recovery.

**Contributors:** Both authors did the literature search and wrote, revised, and edited the manuscript.

**Competing interests:** We have read and understood BMJ policy on declaration of interests and declare the following interests: JLK has received consulting fees from Astute Medical, Sphingotec, and Pfizer and research fees from Astute Medical, Bioporto, NxStage Medical, and Satellite Healthcare for work in biomarkers of AKI, not specific to SA-AKI.

**Provenance and peer review:** Commissioned; externally peer reviewed.

- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315:801-10. 10.1001/jama.2016.0287 pmid:26903338.
- Shankar-Hari M, Phillips GS, Levy ML, et al. Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315:775-87. 10.1001/jama.2016.0289 pmid:26903336.
- Bone RC, Balk RA, Cerra FB, et al. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992;101:1644-55. 10.1378/chest.101.6.1644 pmid:1303622.
- Levy MM, Fink MP, Marshall JC, et al. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 2003;31:1250-6. 10.1097/01.CCM.0000050454.01978.3B pmid:12682500.
- Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11:R31. 10.1186/cc5713 pmid:17331245.
- Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204-12. 10.1186/cc2872 pmid:15312219.
- KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl* 2012;2:1-138.
- Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. *BMJ* 2016;353:i1585. 10.1136/bmj.i1585 pmid:27217054.
- Sprung CL, Sakr Y, Vincent JL, et al. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence In Acutely Ill Patients (SOAP) study. *Intensive Care Med* 2006;32:421-7. 10.1007/s00134-005-0039-8 pmid:16479382.
- Alberti C, Brun-Buisson C, Goodman SV, et al. European Sepsis Group. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. *Am J Respir Crit Care Med* 2003;168:77-84. 10.1164/rccm.200208-785OC pmid:12702548.
- Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. *Lancet* 2013;381:774-5. 10.1016/S0140-6736(12)61815-7 pmid:23472921.
- Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. *Crit Care Med* 1998;26:1793-800. 10.1097/00003246-199811000-00016 pmid:9824069.
- Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. *JAMA* 2001;286:1754-8. 10.1001/jama.286.14.1754 pmid:11594901.
- Churpek MM, Snyder A, Han X, et al. QuickSepsis-related Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and Early Warning Scores for Detecting Clinical Deterioration in Infected Patients outside the Intensive Care Unit. *Am J Respir Crit Care Med* 2017;195:906-11. 10.1164/rccm.201604-0854OC pmid:27649072.
- Mao Q, Jay M, Hoffman JL, et al. Multicenter validation of a sepsis prediction algorithm using only vital sign data in the emergency department, general ward and ICU. *BMJ Open* 2018;8:e017833. 10.1136/bmjopen-2017-017833 pmid:29374661.
- Brivet FG, Kleinknecht DJ, Lohr P, Landais PJ. French Study Group on Acute Renal Failure. Acute renal failure in intensive care units--causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. *Crit Care Med* 1996;24:192-8. 10.1097/00003246-199602000-00003 pmid:8605788.
- Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. *Am J Med* 1998;104:343-8. 10.1016/S0002-9343(98)00058-8 pmid:9576407.
- de Mendonça A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. *Intensive Care Med* 2000;26:915-21. 10.1007/s001340051281 pmid:10990106.
- Joannidis M, Metnitz B, Bauer P, et al. Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. *Intensive Care Med* 2009;35:1692-702. 10.1007/s00134-009-1530-4 pmid:19547955.
- Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML. Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. *Crit Care Med* 2009;37:2552-8. 10.1097/CCM.0b013e3181a5906f pmid:19602973.
- Kellum JA, Lameire N. KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Crit Care* 2013;17:204. 10.1186/cc11454 pmid:23394211.
- Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med* 2015;41:1411-23. 10.1007/s00134-015-3934-7 pmid:26162677.
- Endre ZH, Kellum JA, Di Somma S, et al. Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. *Contrib Nephrol* 2013;182:30-44. 10.1159/000349964 pmid:23689654.
- Chawla LS, Bellomo R, Bihorac A, et al. Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. *Nat Rev Nephrol* 2017;13:241-57. 10.1038/nrneph.2017.2 pmid:28239173.
- Uchino S, Kellum JA, Bellomo R, et al. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 2005;294:813-8. 10.1001/jama.294.7.813 pmid:16106006.
- Yegenaga I, Hoste E, Van Biesen W, et al. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. *Am J Kidney Dis* 2004;43:817-24. 10.1053/ajkd.2003.12.045 pmid:15112172.
- Bagshaw SM, Lapinsky S, Dial S, et al. Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. *Intensive Care Med* 2009;35:871-81. 10.1007/s00134-008-1367-2 pmid:19066848.
- Perner A, Ceconi M, Cronhjort M, et al. Expert statement for the management of hypovolemia in sepsis. *Intensive Care Med* 2018;44:791-8. 10.1007/s00134-018-5177-x pmid:29696295.
- Mehta RL, Bouchard J, Soroko SB, et al. Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. *Intensive Care Med* 2011;37:241-8. 10.1007/s00134-010-2089-9 pmid:21152901.
- Morrell ED, Kellum JA, Pastor-Soler NM, Hallows KR. Septic acute kidney injury: molecular mechanisms and the importance of stratification and targeting therapy. *Crit Care* 2014;18:501. 10.1186/s13054-014-0501-5 pmid:25575158.
- Bagshaw SM, Uchino S, Bellomo R, et al. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. *Clin J Am Soc Nephrol* 2007;2:431-9. 10.2215/CJN.03681106 pmid:17699448.
- Bouchard J, Acharya A, Cerda J, et al. A Prospective International Multicenter Study of AKI in the Intensive Care Unit. *Clin J Am Soc Nephrol* 2015;10:1324-31. 10.2215/CJN.04360514 pmid:26195505.
- Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003;348:1546-54. 10.1056/NEJMoa022139 pmid:12700374.
- McPherson D, Griffiths C, Williams M, et al. Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010. *BMJ Open* 2013;3:e002586. 10.1136/bmjopen-2013-002586 pmid:23913771.
- Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. *JAMA* 2014;311:1308-16. 10.1001/jama.2014.2637 pmid:24638143.

- 36 Kadri SS, Rhee C, Strich JR, et al. Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data. *Chest* 2017;151:278-85. 10.1016/j.chest.2016.07.010 PMID:27452768.
- 37 Chertow GM, Soroko SH, Paganini EP, et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. *Kidney Int* 2006;70:1120-6. 10.1038/sj.ki.5001579 PMID:16850028.
- 38 Thakar CV, Liangos O, Yared JP, et al. ARF after open-heart surgery: Influence of gender and race. *Am J Kidney Dis* 2003;41:742-51. 10.1016/S0272-6386(03)00021-0 PMID:12666060.
- 39 Pannu N, James M, Hemmelgarn BR, Dong J, Tonelli M, Klarenbach S. Alberta Kidney Disease Network. Modification of outcomes after acute kidney injury by the presence of CKD. *Am J Kidney Dis* 2011;58:206-13. 10.1053/j.ajkd.2011.01.028 PMID:21496979.
- 40 Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. *Crit Care* 2005;9:R700-9. 10.1186/cc3879 PMID:16280066.
- 41 Wiedermann CJ, Wiedermann W, Joannidis M. Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. *Intensive Care Med* 2010;36:1657-65. 10.1007/s00134-010-1928-z PMID:20517593.
- 42 Lima RS, Marques CN, Silva Júnior GB, et al. Comparison between early and delayed acute kidney injury secondary to infectious disease in the intensive care unit. *Int Urol Nephrol* 2008;40:731-9. 10.1007/s11255-008-9352-9 PMID:18368509.
- 43 Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. *Nat Rev Nephrol* 2014;10:193-207. 10.1038/nrneph.2013.282 PMID:24445744.
- 44 Hobson C, Ozrazgat-Baslanti T, Kuxhausen A, et al. Cost and Mortality Associated With Postoperative Acute Kidney Injury. *Ann Surg* 2015;261:1207-14. 10.1097/SLA.0000000000000732 PMID:24887982.
- 45 Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol* 2005;16:3365-70. 10.1681/ASN.2004090740 PMID:16177006.
- 46 Bernier-Jean A, Beaubien-Souligny W, Goupil R, et al. Diagnosis and outcomes of acute kidney injury using surrogate and imputation methods for missing preadmission creatinine values. *BMC Nephrol* 2017;18:141. 10.1186/s12882-017-0552-3 PMID:28454562.
- 47 Zhao B, Lu Q, Cheng Y, et al. TRIB3-AKI Consortium \*. A Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury. *Am J Respir Crit Care Med* 2017;195:482-90. 10.1164/rccm.201603-05180C PMID:27576016.
- 48 Jin K, Murugan R, Sileanu FE, et al. Intensive Monitoring of Urine Output Is Associated With Increased Detection of Acute Kidney Injury and Improved Outcomes. *Chest* 2017;152:972-9. 10.1016/j.chest.2017.05.011 PMID:28527880.
- 49 Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G. Classifying AKI by Urine Output versus Serum Creatinine Level. *J Am Soc Nephrol* 2015;26:2231-8. 10.1681/ASN.2014070724 PMID:25568178.
- 50 Quan S, Pannu N, Wilson T, et al. Prognostic implications of adding urine output to serum creatinine measurements for staging of acute kidney injury after major surgery: a cohort study. *Nephrol Dial Transplant* 2016;31:2049-56. 10.1093/ndt/gfw374 PMID:27941063.
- 51 Chawla LS, Dommu A, Berger A, Shih S, Patel SS. Urinary sediment cast scoring index for acute kidney injury: a pilot study. *Nephron Clin Pract* 2008;110:c145-50. 10.1159/000166605 PMID:18953176.
- 52 Perazella MA, Coca SG, Hall IE, Iyanam U, Korashy M, Parikh CR. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. *Clin J Am Soc Nephrol* 2010;5:402-8. 10.2215/CJN.06960909 PMID:20089493.
- 53 Bagshaw SM, Haase M, Haase-Fielitz A, Bennett M, Devarajan P, Bellomo R. A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury. *Nephrol Dial Transplant* 2012;27:582-8. 10.1093/ndt/gfr331 PMID:21669886.
- 54 Neyra JA, Manllo J, Li X, Jacobsen G, Yee J, Yessayan L. AKICI Study Group. Association of de novo dipstick albuminuria with severe acute kidney injury in critically ill septic patients. *Nephron Clin Pract* 2014;128:373-80. 10.1159/000368902 PMID:25591812.
- 55 Neyra JA, Li X, Yessayan L, Adams-Huet B, Yee J, Toto RD. Acute Kidney Injury in Critical Illness Study Group. Dipstick albuminuria and acute kidney injury recovery in critically ill septic patients. *Nephrology (Carlton)* 2016;21:512-8. 10.1111/nep.12637 PMID:26421662.
- 56 McMahon BA, Koyner JL. Risk Stratification for Acute Kidney Injury: Are Biomarkers Enough? *Adv Chronic Kidney Dis* 2016;23:167-78. 10.1053/ajkd.2016.03.001 PMID:27113693.
- 57 Huen SC, Parikh CR. Predicting acute kidney injury after cardiac surgery: a systematic review. *Ann Thorac Surg* 2012;93:337-47. 10.1016/j.athoracsur.2011.09.010 PMID:22186469.
- 58 Mehta RH, Grab JD, O'Brien SM, et al. Society of Thoracic Surgeons National Cardiac Surgery Database Investigators. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. *Circulation* 2006;114:2208-16, quiz 2208. 10.1161/CIRCULATIONAHA.106.635573 PMID:17088458.
- 59 Palomba H, de Castro I, Neto AL, Lage S, Yu L. Acute kidney injury prediction following elective cardiac surgery: AKICS Score. *Kidney Int* 2007;72:624-31. 10.1038/sj.ki.5002419 PMID:17622275.
- 60 Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP. A clinical score to predict acute renal failure after cardiac surgery. *J Am Soc Nephrol* 2005;16:162-8. 10.1681/ASN.2004040331 PMID:15563569.
- 61 Wijeyesundera DN, Karkouti K, Dupuis JY, et al. Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery. *JAMA* 2007;297:1801-9. 10.1001/jama.297.16.1801 PMID:17456822.
- 62 Uchino S, Bellomo R, Morimatsu H, et al. Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. External validation of severity scoring systems for acute renal failure using a multicenter database. *Crit Care Med* 2005;33:1961-7. 10.1097/01.CCM.0000172279.66229.07 PMID:16148466.
- 63 Liaño F, Gallego A, Pascual J, et al. Prognosis of acute tubular necrosis: an extended prospectively contrasted study. *Nephron* 1993;63:21-31. 10.1159/000187139 PMID:8446248.
- 64 Demirjian S, Chertow GM, Zhang JH, et al. VA/NIH Acute Renal Failure Trial Network. Model to predict mortality in critically ill adults with acute kidney injury. *Clin J Am Soc Nephrol* 2011;6:2114-20. 10.2215/CJN.02900311 PMID:21896828.
- 65 da Hora Passos R, Ramos JG, Mendonça EJ, et al. A clinical score to predict mortality in septic acute kidney injury patients requiring continuous renal replacement therapy: the HELENICC score. *BMC Anesthesiol* 2017;17:21. 10.1186/s12871-017-0312-8 PMID:28173756.
- 66 Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA* 1993;270:2957-63. 10.1001/jama.1993.03510240069035 PMID:8254858.
- 67 Ohnuma T, Uchino S, Toki N, et al. JSEPTIC (Japanese Society for Physicians and Trainees in Intensive Care) Clinical Trial Group. External Validation for Acute Kidney Injury Severity Scores: A Multicenter Retrospective Study in 14 Japanese ICUs. *Am J Nephrol* 2015;42:57-64. 10.1159/000439118 PMID:26337793.
- 68 Basu RK, Wang Y, Wong HR, Chawla LS, Wheeler DS, Goldstein SL. Incorporation of biomarkers with the renal angina index for prediction of severe AKI in critically ill children. *Clin J Am Soc Nephrol* 2014;9:654-62. 10.2215/CJN.09720913 PMID:24677554.
- 69 Rizk DV, Meier D, Sandoval RM, et al. A Novel Method for Rapid Bedside Measurement of GFR. *J Am Soc Nephrol* 2018;29:1609-13. 10.1681/ASN.2018020160 PMID:29748326.
- 70 Kim H, Hur M, Lee S, et al. GREAT Network. Proenkephalin, Neutrophil Gelatinase-Associated Lipocalin, and Estimated Glomerular Filtration Rates in Patients With Sepsis. *Ann Lab Med* 2017;37:388-97. 10.3343/alm.2017.37.5.388 PMID:28643487.
- 71 Mårtensson J, Martling CR, Oldner A, Bell M. Impact of sepsis on levels of plasma cystatin C in AKI and non-AKI patients. *Nephrol Dial Transplant* 2012;27:576-81. 10.1093/ndt/gfr358 PMID:21765189.
- 72 Dai X, Zeng Z, Fu C, Zhang S, Cai Y, Chen Z. Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury. *Crit Care* 2015;19:223. 10.1186/s13054-015-0941-6 PMID:25944130.
- 73 Honore PM, Nguyen HB, Gong M, et al. Sapphire and Topaz Investigators. Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis. *Crit Care Med* 2016;44:1851-60. 10.1097/CCM.0000000000001827 PMID:27355527.
- 74 Ko GJ, Grigoryev DN, Linfert D, et al. Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition. *Am J Physiol Renal Physiol* 2010;298:F1472-83. 10.1152/ajprenal.00619.2009 PMID:20181666.
- 75 McWilliam SJ, Antoine DJ, Jorgensen AL, Smyth RL, Pirmohamed M. Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin. *Sci Rep* 2018;8:5094. 10.1038/s41598-018-23466-4 PMID:29572451.
- 76 de Geus HR, Betjes MG, Schaick Rv, Groeneveld JA. Plasma NGAL similarly predicts acute kidney injury in sepsis and nonsepsis. *Biomark Med* 2013;7:415-21. 10.2217/bmm.13.5 PMID:23734805.
- 77 Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. *J Am Coll Cardiol* 2011;57:1752-61. 10.1016/j.jacc.2010.11.051 PMID:21511111.
- 78 Nickolas TL, O'Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. *Ann Intern Med* 2008;148:810-9. 10.7326/0003-4819-148-11-200806030-00003 PMID:18519927.
- 79 Md Ralib A, Mat Nor MB, Pickering JW. Plasma Neutrophil Gelatinase-Associated Lipocalin diagnosed acute kidney injury in patients with systemic inflammatory disease and sepsis. *Nephrology (Carlton)* 2017;22:412-9. 10.1111/nep.12796 PMID:27062515.
- 80 de Geus HR, Fortrie G, Betjes MG, van Schaik RH, Groeneveld AB. Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients. *BMC Nephrol* 2013;14:273. 10.1186/1471-2369-14-273 PMID:24321290.
- 81 Chen LX, Koyner JL. Biomarkers in Acute Kidney Injury. *Crit Care Clin* 2015;31:633-48. 10.1016/j.ccc.2015.06.002 PMID:26410134.

- 82 Hodgson LE, Sarnowski A, Roderick PJ, Dimitrov BD, Venn RM, Forni LG. Systematic review of prognostic prediction models for acute kidney injury (AKI) in general hospital populations. *BMJ Open* 2017;7:e016591. 10.1136/bmjopen-2017-016591 pmid:28963291.
- 83 Bhattacharjee P, Edelson DP, Churpek MM. Identifying Patients With Sepsis on the Hospital Wards. *Chest* 2017;151:898-907. 10.1016/j.chest.2016.06.020 pmid:27374948.
- 84 Koynier JL, Adhikari R, Edelson DP, Churpek MM. Development of a Multicenter Ward-Based AKI Prediction Model. *Clin J Am Soc Nephrol* 2016;11:1935-43. 10.2215/CJN.00280116 pmid:27633727.
- 85 Gómez H, Kellum JA. Sepsis-induced acute kidney injury. *Curr Opin Crit Care* 2016;22:546-53. 10.1097/MCC.0000000000000356 pmid:27661757.
- 86 Keir I, Kellum JA. Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations. *J Vet Emerg Crit Care (San Antonio)* 2015;25:200-9. 10.1111/vec.12297 pmid:25845505.
- 87 Pool R, Gomez H, Kellum JA. Mechanisms of Organ Dysfunction in Sepsis. *Crit Care Clin* 2018;34:63-80. 10.1016/j.ccc.2017.08.003 pmid:29149942.
- 88 Fani F, Regolisti G, Delsante M, et al. Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury. *J Nephrol* 2018;31:351-9. 10.1007/s40620-017-0452-4 pmid:29273917.
- 89 Langenberg C, Gobe G, Hood S, May CN, Bellomo R. Renal histopathology during experimental septic acute kidney injury and recovery. *Crit Care Med* 2014;42:e58-67. 10.1097/CCM.0b013e3182a639da pmid:24126439.
- 90 Maiden MJ, Otto S, Brealley JK, et al. Structure and Function of the Kidney in Septic Shock. A Prospective Controlled Experimental Study. *Am J Respir Crit Care Med* 2016;194:692-700. 10.1164/rccm.201511-2285OC pmid:26967568.
- 91 Nemzek JA, Huguenin KM, Opp MR. Modeling sepsis in the laboratory: merging sound science with animal well-being. *Comp Med* 2008;58:120-8. pmid:18524169.
- 92 Prowle JR, Ishikawa K, May CN, Bellomo R. Renal plasma flow and glomerular filtration rate during acute kidney injury in man. *Ren Fail* 2010;32:349-55. 10.3109/08860221003611695 pmid:20370451.
- 93 Redfors B, Bragadottir G, Sellgren J, Swärd K, Ricksten SE. Effects of norepinephrine on renal perfusion, filtration and oxygenation in vasodilatory shock and acute kidney injury. *Intensive Care Med* 2011;37:60-7. 10.1007/s00134-010-2057-4 pmid:20949349.
- 94 Prowle JR, Molan MP, Hornsey E, Bellomo R. Measurement of renal blood flow by phase-contrast magnetic resonance imaging during septic acute kidney injury: a pilot investigation. *Crit Care Med* 2012;40:1768-76. 10.1097/CCM.0b013e318246bd85 pmid:22487999.
- 95 National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Precision Medicine Project. 2018. <https://www.niddk.nih.gov/research-funding/research-programs/kidney-precision-medicine-project-kpmp>.
- 96 Post EH, Kellum JA, Bellomo R, Vincent JL. Renal perfusion in sepsis: from macro- to microcirculation. *Kidney Int* 2017;91:45-60. 10.1016/j.kint.2016.07.032 pmid:27692561.
- 97 Chelazzi C, Villa G, Mancinelli P, De Gaudio AR, Adem Bri C. Glycocalyx and sepsis-induced alterations in vascular permeability. *Crit Care* 2015;19:26. 10.1186/s13054-015-0741-z pmid:25887223.
- 98 Tsukahara Y, Morisaki T, Kojima M, Uchiyama A, Tanaka M. iNOS expression by activated neutrophils from patients with sepsis. *ANZ J Surg* 2001;71:15-20. 10.1046/j.1440-1622.2001.02025.x pmid:11167591.
- 99 Guerci P, Ergin B, Ince C. The macro- and microcirculation of the kidney. *Best Pract Res Clin Anaesthesiol* 2017;31:315-29. 10.1016/j.bpa.2017.10.002 pmid:29248139.
- 100 Lankadeva YR, Kosaka J, Evans RG, Bailey SR, Bellomo R, May CN. Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury. *Kidney Int* 2016;90:100-8. 10.1016/j.kint.2016.02.017 pmid:27165831.
- 101 Lankadeva YR, Kosaka J, Evans RG, Bellomo R, May CN. Urinary Oxygenation as a Surrogate Measure of Medullary Oxygenation During Angiotensin II Therapy in Septic Acute Kidney Injury. *Crit Care Med* 2018;46:e41-8. 10.1097/CCM.0000000000002797 pmid:29077618.
- 102 Schneider AG, Calzavacca P, Schelleman A, et al. Contrast-enhanced ultrasound evaluation of renal microcirculation in sheep. *Intensive Care Med Exp* 2014;2:33. 10.1186/s40635-014-0033-y pmid:26266930.
- 103 Tumlin JA, Murugan R, Deane AM, et al. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. *Crit Care Med* 2018;46:949-57. 10.1097/CCM.0000000000003092 pmid:29509568.
- 104 Rowan KM, Angus DC, Bailey M, et al. PRISM Investigators. Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. *N Engl J Med* 2017;376:2223-34. 10.1056/NEJMoa1701380 pmid:28320242.
- 105 Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001;345:1368-77. 10.1056/NEJMoa010307 pmid:11794169.
- 106 Kellum JA, Pike F, Yealy DM, Huang DT, Shapiro NI, Angus DC. and the Protocol-based Care for Early Septic Shock Investigators (ProCESS) Investigators. Relationship Between Alternative Resuscitation Strategies, Host Response and Injury Biomarkers, and Outcome in Septic Shock: Analysis of the Protocol-Based Care for Early Septic Shock Study. *Crit Care Med* 2017;45:438-45. 10.1097/CCM.0000000000002206 pmid:28079606.
- 107 Wiedemann HP, Wheeler AP, Bernard GR, et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006;354:2564-75. 10.1056/NEJMoa062200 pmid:16714767.
- 108 Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. *Crit Care* 2008;12:R74. 10.1186/cc6916 pmid:18533029.
- 109 Liu KD, Thompson BT, Ancukiewicz M, et al. National Institutes of Health National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. *Crit Care Med* 2011;39:2665-71. 10.1097/CCM.0b013e318228234b pmid:21785346.
- 110 Grams ME, Estrella MM, Coresh J, Brower RG, Liu KD. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Fluid balance, diuretic use, and mortality in acute kidney injury. *Clin J Am Soc Nephrol* 2011;6:966-73. 10.2215/CJN.08781010 pmid:21393482.
- 111 Glassford NJ, Bellomo R. Does Fluid Type and Amount Affect Kidney Function in Critical Illness? *Crit Care Clin* 2018;34:279-98. 10.1016/j.ccc.2017.12.006 pmid:29482907.
- 112 Perner A, Prowle J, Joannidis M, Young P, Hjortrup PB, Pettit V. Fluid management in acute kidney injury. *Intensive Care Med* 2017;43:807-15. 10.1007/s00134-017-4817-x pmid:28470347.
- 113 Howell MD, Davis AM. Management of Sepsis and Septic Shock. *JAMA* 2017;317:847-8. 10.1001/jama.2017.0131 pmid:28114603.
- 114 Bouchard J, Soroko SB, Chertow GM, et al. Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. *Kidney Int* 2009;76:422-7. 10.1038/ki.2009.159 pmid:19436332.
- 115 Brunkhorst FM, Engel C, Bloos F, et al. German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008;358:125-39. 10.1056/NEJMoa070716 pmid:18184958.
- 116 Perner A, Haase N, Guttormsen AB, et al. 6S Trial Group Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med* 2012;367:124-34. 10.1056/NEJMoa1204242 pmid:22738085.
- 117 Myburgh JA, Finfer S, Bellomo R, et al. CHEST Investigators Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *N Engl J Med* 2012;367:1901-11. 10.1056/NEJMoa1209759 pmid:23075127.
- 118 Haase N, Wetterslev J, Winkel P, Perner A. Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. *Intensive Care Med* 2013;39:2126-34. 10.1007/s00134-013-3111-9 pmid:24081433.
- 119 Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. *JAMA* 2013;309:678-88. 10.1001/jama.2013.430 pmid:23423413.
- 120 Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. SAFE Study Investigators. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. *Intensive Care Med* 2011;37:86-96. 10.1007/s00134-010-2039-6 pmid:20924555.
- 121 Caironi P, Tognoni G, Masson S, et al. ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. *N Engl J Med* 2014;370:1412-21. 10.1056/NEJMoa1305727 pmid:24635772.
- 122 Jiang L, Jiang S, Zhang M, Zheng Z, Ma Y. Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis. *PLoS One* 2014;9:e114666. 10.1371/journal.pone.0114666 pmid:25474401.
- 123 Xu JY, Chen QH, Xie JF, et al. Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials. *Crit Care* 2014;18:702. 10.1186/s13054-014-0702-y pmid:25499187.
- 124 Raghunathan K, Bonavia A, Nathanson BH, et al. Association between Initial Fluid Choice and Subsequent In-hospital Mortality during the Resuscitation of Adults with Septic Shock. *Anesthesiology* 2015;123:1385-93. 10.1097/ALN.0000000000000861 pmid:26414499.
- 125 Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. *JAMA* 2012;308:1566-72. 10.1001/jama.2012.13356 pmid:23073953.
- 126 Shaw AD, Bagshaw SM, Goldstein SL, et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. *Ann Surg* 2012;255:821-9. 10.1097/SLA.0b013e31825074f5 pmid:22470070.
- 127 Young P, Bailey M, Beasley R, et al. SPLIT Investigators ANZICS CTG. Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial. *JAMA* 2015;314:1701-10. 10.1001/jama.2015.12334 pmid:26444692.
- 128 Raghunathan K, Shaw A, Nathanson B, et al. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis\*. *Crit Care Med* 2014;42:1585-91. 10.1097/CCM.0000000000000305 pmid:24674927.
- 129 Self WH, Semler MW, Wanderer JP, et al. SALT-ED Investigators. Balanced Crystalloids versus Saline in Noncritically Ill Adults. *N Engl J Med* 2018;378:819-28. 10.1056/NEJMoa1711586 pmid:29485926.

- 130 Semler MW, Self WH, Wanderer JP, et al. SMART Investigators and the Pragmatic Critical Care Research Group. Balanced Crystalloids versus Saline in Critically Ill Adults. *N Engl J Med* 2018;378:829-39. 10.1056/NEJMoa1711584 pmid:29485925.
- 131 Gordon AC, Mason AJ, Thirunavukkarasu N, et al. VANISH Investigators. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. *JAMA* 2016;316:509-18. 10.1001/jama.2016.10485 pmid:27483065.
- 132 Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med* 2001;29:1526-31. 10.1097/00003246-200108000-00005 pmid:11505120.
- 133 Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock. *JAMA* 2017;317:1433-42. 10.1001/jama.2017.2841 pmid:28322415.
- 134 Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. *N Engl J Med* 2016;375:1638-48. 10.1056/NEJMoa1609409 pmid:27705084.
- 135 Khanna A, English SW, Wang XS, et al. ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. *N Engl J Med* 2017;377:419-30. 10.1056/NEJMoa1704154 pmid:28528561.
- 136 De Backer D, Biston P, Devriendt J, et al. SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010;362:779-89. 10.1056/NEJMoa0907118 pmid:20200382.
- 137 Lauzier F, Lévy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. *Intensive Care Med* 2006;32:1782-9. 10.1007/s00134-006-0378-0 pmid:17019548.
- 138 Morelli A, Ertmer C, Rehberg S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. *Crit Care* 2008;12:R143. 10.1186/cc7121 pmid:19017409.
- 139 Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. *Intensive Care Med* 2008;34:2226-34. 10.1007/s00134-008-1219-0 pmid:18654759.
- 140 Hallengren M, Åstrand P, Eksborg S, Barle H, Frostell C. Septic shock and the use of norepinephrine in an intermediate care unit: Mortality and adverse events. *PLoS One* 2017;12:e0183073. 10.1371/journal.pone.0183073 pmid:28837628.
- 141 Russell JA, Walley KR, Singer J, et al. VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008;358:877-87. 10.1056/NEJMoa067373 pmid:18305265.
- 142 Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. *Intensive Care Med* 2005;31:638-44. 10.1007/s00134-005-2619-z pmid:15812624.
- 143 Asfar P, Meziani F, Hamel JF, et al. SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. *N Engl J Med* 2014;370:1583-93. 10.1056/NEJMoa1312173 pmid:24635770.
- 144 Drury DR, Henry JP, Goodman J. THE EFFECTS OF CONTINUOUS PRESSURE BREATHING ON KIDNEY FUNCTION. *J Clin Invest* 1947;26:945-51. 10.1172/JCI101889 pmid:16695498.
- 145 van den Akker JP, Egal M, Groeneveld AB. Invasive mechanical ventilation as a risk factor for acute kidney injury in the critically ill: a systematic review and meta-analysis. *Crit Care* 2013;17:R98. 10.1186/cc12743 pmid:23710662.
- 146 Broden CC. Acute renal failure and mechanical ventilation: reality or myth? *Crit Care Nurse* 2009;29:62-75, quiz 76. 10.4037/ccn2009267 pmid:19339448.
- 147 Koyner JL, Murray PT. Mechanical ventilation and lung-kidney interactions. *Clin J Am Soc Nephrol* 2008;3:562-70. 10.2215/CJN.03090707 pmid:18256378.
- 148 Kuiper JW, Groeneveld AB, Slutsky AS, Plötz FB. Mechanical ventilation and acute renal failure. *Crit Care Med* 2005;33:1408-15. 10.1097/O1.CCM.0000165808.30416.EF pmid:15942363.
- 149 Daher EF, Marques CN, Lima RS, et al. Acute kidney injury in an infectious disease intensive care unit - an assessment of prognostic factors. *Swiss Med Wkly* 2008;138:128-33. pmid:18330732.
- 150 Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342:1301-8. 10.1056/NEJM200005043421801 pmid:10793162.
- 151 Cavalcanti AB, Suzumura EA, Laranjeira LN, et al. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. *JAMA* 2017;318:1335-45. 10.1001/jama.2017.14171 pmid:28973363.
- 152 Mercat A, Richard JC, Vieille B, et al. Expiratory Pressure (Express) Study Group. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2008;299:646-55. 10.1001/jama.299.6.646 pmid:18270353.
- 153 Frat JP, Thille AW, Mercat A, et al. FLORALI Study Group REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med* 2015;372:2185-96. 10.1056/NEJMoa1503326 pmid:25981908.
- 154 Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. *JAMA* 2016;315:2435-41. 10.1001/jama.2016.6338 pmid:27179847.
- 155 Mehta RL, Pascual MT, Soroko S, Chertow GM. PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. *JAMA* 2002;288:2547-53. 10.1001/jama.288.20.2547 pmid:12444861.
- 156 Uchino S, Doig GS, Bellomo R, et al. Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Diuretics and mortality in acute renal failure. *Crit Care Med* 2004;32:1669-77. 10.1097/O1.CCM.0000132892.51063.2F pmid:15286542.
- 157 Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. *BMJ* 2006;333:420. 10.1136/bmj.38902.605347.7C pmid:16861256.
- 158 Peters E, Heuberger JAAC, Tiessen R, et al. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers. *Clin Pharmacokinet* 2016;55:1227-37. 10.1007/s40262-016-0399-y pmid:27147514.
- 159 Peters E, Mehta RL, Murray PT, et al. Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI). *BMJ Open* 2016;6:e012371. 10.1136/bmjopen-2016-012371 pmid:27678541.
- 160 Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T. Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. *Clin Biochem* 2002;35:455-61. 10.1016/S0009-9120(02)00330-2 pmid:12413606.
- 161 Pickkers P, Mehta RL, Murray PT, et al. STOP-AKI Investigators. Effect of Human Recombinant Alkaline Phosphatase for 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial. *JAMA* 2018;320:1998-2009. 10.1001/jama.2018.14283 pmid:30357272.
- 162 DiRocco DP, Bisi J, Roberts P, et al. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. *Am J Physiol Renal Physiol* 2014;306:F379-88. 10.1152/ajprenal.00475.2013 pmid:24338822.
- 163 Cantaluppi V, Medica D, Quercia AD, et al. Perfluorocarbon solutions limit tubular epithelial cell injury and promote CD133+ kidney progenitor differentiation: potential use in renal assist devices for sepsis-associated acute kidney injury and multiple organ failure. *Nephrol Dial Transplant* 2018;33:1110-21. 10.1093/ndt/gfx328 pmid:29267971.
- 164 Yu G, Liu Q, Dong X, et al. Inhibition of inflammation using diacerein markedly improved renal function in endotoxemic acute kidney injured mice. *Cell Mol Biol Lett* 2018;23:38. 10.1186/s11658-018-0107-z pmid:30140293.
- 165 Luo CJ, Luo F, Zhang L, et al. Knockout of interleukin-17A protects against sepsis-associated acute kidney injury. *Ann Intensive Care* 2016;6:56. 10.1186/s13613-016-0157-1 pmid:27334720.
- 166 Murugan R, Weissfeld L, Yende S, Singbartl K, Angus DC, Kellum JA. Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators. Association of statin use with risk and outcome of acute kidney injury in community-acquired pneumonia. *Clin J Am Soc Nephrol* 2012;7:895-905. 10.2215/CJN.07100711 pmid:22461537.
- 167 Deshpande A, Pasupuleti V, Rothberg MB. Statin therapy and mortality from sepsis: a meta-analysis of randomized trials. *Am J Med* 2015;128:410-7.e1. 10.1016/j.amjmed.2014.10.057 pmid:25526798.
- 168 Ergin B, Guerci P, Zafrani L, et al. Effects of N-acetylcysteine (NAC) supplementation in resuscitation fluids on renal microcirculatory oxygenation, inflammation, and function in a rat model of endotoxemia. *Intensive Care Med* 2016;4:29. 10.1186/s40635-016-0106-1 pmid:27671340.
- 169 Campos R, Shimizu MH, Volpini RA, et al. N-acetylcysteine prevents pulmonary edema and acute kidney injury in rats with sepsis submitted to mechanical ventilation. *Am J Physiol Lung Cell Mol Physiol* 2012;302:L640-50. 10.1152/ajplung.00097.2011 pmid:22268121.
- 170 Weisbord SD, Gallagher M, Jneid H, et al. PRESERVE Trial Group. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. *N Engl J Med* 2018;378:603-14. 10.1056/NEJMoa1710933 pmid:29130810.
- 171 Komisarof JA, Gilkey GM, Peters DM, Koudelka CW, Meyer MM, Smith SM. N-acetylcysteine for patients with prolonged hypotension as prophylaxis for acute renal failure (NEPHRON). *Crit Care Med* 2007;35:435-41. 10.1097/O1.CCM.0000253816.83011.DB pmid:17205018.
- 172 van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359-67. 10.1056/NEJMoa011300 pmid:11794168.
- 173 Finfer S, Chittock DR, Su SY, et al. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360:1283-97. 10.1056/NEJMoa0810625 pmid:19318384.
- 174 Corwin HL, Gettinger A, Pearl RG, et al. EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. *JAMA* 2002;288:2827-35. 10.1001/jama.288.22.2827 pmid:12472324.
- 175 Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). *Kidney Int* 2010;77:1020-30. 10.1038/ki.2010.25 pmid:20164823.
- 176 Annane D, Renault A, Brun-Buisson C, et al. CRICS-TRIGGERSEP Network. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. *N Engl J Med* 2018;378:809-18. 10.1056/NEJMoa1705716 pmid:29490185.

- 177 Venkatesh B, Finfer S, Cohen J, et al. ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. *N Engl J Med* 2018;378:797–808. 10.1056/NEJMoa1705835 pmid:29347874.
- 178 Plickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. *Crit Care* 2012;16:R14. 10.1186/cc11159 pmid:22269279.
- 179 Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial. *Ann Am Thorac Soc* 2017;14:737–41. 10.1513/AnnalsATS.201608-656BC pmid:28207287.
- 180 ClinicalTrials.gov. Phase 2 Study of reltecedim vs placebo in patients with sepsis-associated acute kidney injury. 2018. <https://clinicaltrials.gov/ct2/show/NCT03403751>.
- 181 ClinicalTrials.gov. Impact of CVHD with adsorption capacity membranes in septic acute kidney injury. 2018. <https://clinicaltrials.gov/ct2/show/NCT01790620>.
- 182 ClinicalTrials.gov. The effect of fluid resuscitation with 0.9% sodium chloride versus balanced crystalloid solution on renal function of sepsis patients. 2018. <https://clinicaltrials.gov/ct2/show/NCT03277677>.
- 183 ClinicalTrials.gov. L-carnitine as an adjunct treatment for septic shock patients with acute kidney injury (CarniSave). 2018. <https://clinicaltrials.gov/ct2/show/NCT02664753>.
- 184 ClinicalTrials.gov. Impact of pediatric acute renal injury in severe sepsis in young adults (IMPRESS-YA). 2018. <https://clinicaltrials.gov/ct2/show/NCT02599844>.
- 185 Gaudry S, Ricard JD, Leclaire C, et al. Acute kidney injury in critical care: experience of a conservative strategy. *J Crit Care* 2014;29:1022–7. 10.1016/j.jccr.2014.07.014 pmid:25123792.
- 186 Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. *JAMA* 2016;315:2190–9. 10.1001/jama.2016.5828 pmid:27209269.
- 187 Palevsky PM, Zhang JH, O'Connor TZ, et al. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 2008;359:7–20. 10.1056/NEJMoa0802639 pmid:18492867.
- 188 Bellomo R, Cass A, Cole L, et al. RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med* 2009;361:1627–38. 10.1056/NEJMoa0902413 pmid:19846848.
- 189 Wald R, Friedrich JO, Bagshaw SM, et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI)—a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project. *Crit Care* 2012;16:R205. 10.1186/cc11835 pmid:23095370.
- 190 Barbar SD, Clere-Jehl R, Bourredjem A, et al. IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. *N Engl J Med* 2018;379:1431–42. 10.1056/NEJMoa1803213 pmid:30304656.
- 191 Payen D, Mateo J, Cavallion JM, Ffaisse F, Floriot C, Vicaute E. Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecine d'Urgence des Hôpitaux extra-Universitaires. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. *Crit Care Med* 2009;37:803–10. 10.1097/CCM.0b013e3181962316 pmid:19237881.
- 192 Gaudry S, Hajage D, Schortgen F, et al. AKIKI Study Group. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. *N Engl J Med* 2016;375:122–33. 10.1056/NEJMoa1603017 pmid:27181456.
- 193 Zhang P, Yang Y, Lv R, Zhang Y, Xie W, Chen J. Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. *Nephrol Dial Transplant* 2012;27:967–73. 10.1093/ndt/gfr486 pmid:21891773.
- 194 Joannes-Boyau O, Honoré PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. *Intensive Care Med* 2013;39:1535–46. 10.1007/s00134-013-2967-z pmid:23740278.
- 195 Park JT, Lee H, Kee YK, et al. HICORES Investigators. High-Dose Versus Conventional-Dose Continuous Venovenous Hemodiafiltration and Patient and Kidney Survival and Cytokine Removal in Sepsis-Associated Acute Kidney Injury: A Randomized Controlled Trial. *Am J Kidney Dis* 2016;68:599–608. 10.1053/j.ajkd.2016.02.049 pmid:27084247.
- 196 Chung KK, Coates EC, Smith DJ Jr, et al. Randomized controlled Evaluation of high-volume hemofiltration in adult burn patients with Septic shock and acute kidney injury (RESCUE) Investigators. High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial. *Crit Care* 2017;21:289. 10.1186/s13054-017-1878-8 pmid:29178943.
- 197 Gaudry S, Hajage D, Schortgen F, et al. Timing of Renal Support and Outcome of Septic Shock and Acute Respiratory Distress Syndrome. A Post Hoc Analysis of the AKIKI Randomized Clinical Trial. *Am J Respir Crit Care Med* 2018;198:58–66. 10.1164/rccm.201706-1255OC pmid:29351007.
- 198 Smith OM, Wald R, Adhikari NK, Pope K, Weir MA, Bagshaw SM. Canadian Critical Care Trials Group. Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. *Trials* 2013;14:320. 10.1186/1745-6215-14-320 pmid:24093950.
- 199 Schefold JC, von Haehling S, Pischowski R, et al. The effect of continuous versus intermittent renal replacement therapy on the outcome of critically ill patients with acute renal failure (CONVINT): a prospective randomized controlled trial. *Crit Care* 2014;18:R11. 10.1186/cc13188 pmid:24405734.
- 200 Vinsonneau C, Camus C, Combes A, et al. Hemodiafefe Study Group. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. *Lancet* 2006;368:379–85. 10.1016/S0140-6736(06)69111-3 pmid:16876666.
- 201 Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. *Crit Care Med* 2008;36:610–7. 10.1097/01.CCM.0b013e3181611F52 pmid:18216610.
- 202 Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. *Crit Care Med* 2013;41:2209–20. 10.1097/CCM.0b013e31828cf412 pmid:23860248.
- 203 Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. *JAMA* 2009;301:2445–52. 10.1001/jama.2009.856 pmid:19531784.
- 204 Dellinger RP, Bagshaw SM, Antonelli M, et al. EUPHRATES Trial Investigators. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. *JAMA* 2018;320:1455–63. 10.1001/jama.2018.14618 pmid:30304428.
- 205 Forni LG, Darmon M, Ostermann M, et al. Renal recovery after acute kidney injury. *Intensive Care Med* 2017;43:855–66. 10.1007/s00134-017-4809-x pmid:28466146.
- 206 Patel SS, Palant CE, Mahajan V, Chawla LS. Sequelae of AKI. *Best Pract Res Clin Anaesthesiol* 2017;31:415–25. 10.1016/j.bpa.2017.08.004 pmid:29248147.
- 207 Cerdá J, Lameire N, Eggers P, et al. Epidemiology of acute kidney injury. *Clin J Am Soc Nephrol* 2008;3:881–6. 10.2215/CJN.04961107 pmid:18216347.
- 208 Kellum JA, Sileanu FE, Bihorac A, Hoste EA, Chawla LS. Recovery after Acute Kidney Injury. *Am J Respir Crit Care Med* 2017;195:784–91. 10.1164/rccm.201604-0799OC pmid:27635668.
- 209 Venot M, Weis L, Clec'h C, et al. Acute Kidney Injury in Severe Sepsis and Septic Shock in Patients with and without Diabetes Mellitus: A Multicenter Study. *PLoS One* 2015;10:e0127411. 10.1371/journal.pone.0127411 pmid:26020231.
- 210 Grams ME, Sang Y, Coresh J, et al. Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data. *Am J Kidney Dis* 2016;67:872–80. 10.1053/j.ajkd.2015.07.022 pmid:26337133.
- 211 Sawhney S, Marks A, Fluck N, McLernon DJ, Prescott GJ, Black C. Acute kidney injury as an independent risk factor for unplanned 90-day hospital readmissions. *BMC Nephrol* 2017;18:9. 10.1186/s12882-016-0430-4 pmid:28061831.
- 212 Brown JR, Hisey WM, Marshall EJ, et al. Acute Kidney Injury Severity and Long-Term Readmission and Mortality After Cardiac Surgery. *Ann Thorac Surg* 2016;102:1482–9. 10.1016/j.athoracsur.2016.04.020 pmid:27319985.
- 213 Prescott HC, Langa KM, Iwashyna TJ. Readmission diagnoses after hospitalization for severe sepsis and other acute medical conditions. *JAMA* 2015;313:1055–7. 10.1001/jama.2015.1410 pmid:25756444.
- 214 Hsu CY. Yes, AKI truly leads to CKD. *J Am Soc Nephrol* 2012;23:967–9. 10.1681/ASN.2012030222 pmid:22499588.
- 215 Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? *J Am Soc Nephrol* 2012;23:979–84. 10.1681/ASN.2011121185 pmid:22460531.
- 216 Christiansen S, Christensen S, Pedersen L, et al. Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury. *Crit Care* 2017;21:326. 10.1186/s13054-017-1903-y pmid:29282093.
- 217 Sawhney S, Marks A, Fluck N, et al. Post-discharge kidney function is associated with subsequent ten-year renal progression risk among survivors of acute kidney injury. *Kidney Int* 2017;92:440–52. 10.1016/j.kint.2017.02.019 pmid:28416224.
- 218 Mehta S, Chauhan K, Patel A, et al. The prognostic importance of duration of AKI: a systematic review and meta-analysis. *BMC Nephrol* 2018;19:91. 10.1186/s12882-018-0876-7 pmid:29673338.
- 219 Go AS, Parikh CR, Iklizler TA, et al. Assessment Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury Study Investigators. The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. *BMC Nephrol* 2010;11:22. 10.1186/1471-2369-11-22 pmid:20799966.
- 220 Husain-Syed F, Ferrari F, Sharma A, et al. Preoperative Renal Functional Reserve Predicts Risk of Acute Kidney Injury After Cardiac Operation. *Ann Thorac Surg* 2018;105:1094–101. 10.1016/j.athoracsur.2017.12.034 pmid:29382510.
- 221 National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management up to the point of renal replacement therapy. 2013. <https://www.nice.org.uk/guidance/cg169>.
- 222 Brochard L, Abroug F, Brenner M, et al. ATS/ERS/ESICM/SCCM/SRLF Ad Hoc Committee on Acute Renal Failure. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. *Am J Respir Crit Care Med* 2010;181:1128–55. 10.1164/rccm.200711-1664ST pmid:20460549.